[
  {
    "id": "41540706",
    "title_en": "[Sulforaphane reduces reactive astrocyte-mediated neuron apoptosis <i>in vitro</i> by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes].",
    "pub_date": "2026 Jan",
    "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
    "abstract_en": "To explore the effects of sulforaphane (SFN) on AÎ²42-activated U87 astrocyte-mediated apoptosis of SH-SY5Y neurons <i>in vitro</i>. U87 cells treated with different concentrations of AÎ²42, SFN or both were examined for changes in cell activity, IL-6 and TNF-Î± mRNA expression, release of IL-6 and TNF-Î± proteins, and expressions of p-p38, p-p65 and GFAP using CCK-8 assay, RT-qPCR, ELISA and Western blotting. SH-SY5Y neurons were co-cultured with U87 astrocytes treated with AÎ²42 alone or in combination with SFN or SB203580 for 24 h, and the changes in Bax protein expression levels and viability of SH-SY5Y cells were examined. The effects of AÎ²42, SFN, and their combination were also observed in astrocytes isolated from mouse brain tissues, and the indirect effects of astrocyte treatmentt on viability of the co-cultured primary neurons were assessed. The viability of U87 astrocytes increased significantly following treatment with 1.25 Î¼mol/L AÎ²42 but decreased after AÎ²42 treatment above 5 Î¼mol/L. SFN treatments for 24 h below 5 Î¼mol/L did not significantly affect U87 cell viability. AÎ²42 treatment significantly increased protein expressions of p-p38, p-p65 and GFAP, mRNA expression levels of IL-6 and TNF-Î±, and IL-6 and TNF-Î± levels in culture supernatant of U87 cells. SH-SY5Y cells co-cultured with AÎ²42-treated U87 cells showed significantly increased protein expressions of Bax, and exhibited lowered viability following co-culture with 5 Î¼mol/L AÎ²42-treated U87 cells. The isolated mouse astrocytes showed lowered viability following AÎ²42 treatment above 10 Î¼mol/L, but SFN treatment below 5 Î¼mol/L for 24 did not obviously affect the cell viability. The primary neurons co-cultured with AÎ²42-treated mouse astrocytes showed significantly lower cell viability than those co-cultured with the astrocytes treated with AÎ²+SFN or AÎ²+SB203580. SFN attenuates astrocyte-mediated neuron apoptosis by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„ç ”ç©¶ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼ç†è§£å¦‚ä½•æ¸›å°‘ç¥ç¶“ç´°èƒæ­»äº¡ã€æ”¹å–„ç¥ç¶“å¥åº·å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘æ¢ç´¢æ–°çš„é é˜²æˆ–æ²»ç™‚æ–¹æ³•ï¼Œç‰¹åˆ¥æ˜¯é‡å°èˆ‡è€åŒ–ç›¸é—œçš„ç–¾ç—…ï¼Œå¦‚é˜¿èŒ²ç½•é»˜ç—‡ç­‰ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿Î²42æ¿€æ´»çš„æ˜Ÿç‹€è† ç´°èƒæ‰€å¼•èµ·çš„ç¥ç¶“ç´°èƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ˜Ÿç‹€è† ç´°èƒå’Œç¥ç¶“ç´°èƒä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨é€™ç¨®ç›¸äº’ä½œç”¨å°ç¥ç¶“ç´°èƒå­˜æ´»çš„å½±éŸ¿ã€‚é€™å°æ–¼ç†è§£ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42å’Œè˜¿è””ç¡«ç´ ä¾†è™•ç†U87æ˜Ÿç‹€è† ç´°èƒï¼Œä¸¦è§€å¯Ÿç´°èƒæ´»æ€§åŠç›¸é—œè›‹ç™½è³ªå’ŒåŸºå› è¡¨é”çš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„å°‡SH-SY5Yç¥ç¶“ç´°èƒèˆ‡è™•ç†éé˜¿Î²42çš„U87æ˜Ÿç‹€è† ç´°èƒå…±åŒåŸ¹é¤Šï¼Œä¸¦æª¢æ¸¬ç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡å’Œå‡‹äº¡ç›¸é—œè›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢æ˜Ÿç‹€è† ç´°èƒï¼Œé€²ä¸€æ­¥æ¢è¨é€™äº›ç´°èƒå°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87æ˜Ÿç‹€è† ç´°èƒæ¥å—é˜¿Î²42è™•ç†å¾Œï¼Œå…¶æ´»æ€§æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦ä¸”æœƒä¿ƒé€²å‡‹äº¡ç›¸é—œè›‹ç™½Baxçš„è¡¨é”ï¼Œå°è‡´SH-SY5Yç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡é™ä½ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†åœ¨ä¸€å®šæ¿ƒåº¦ä¸‹å°æ˜Ÿç‹€è† ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†èƒ½å¤ æ¸›å°‘é˜¿Î²42å°ç¥ç¶“ç´°èƒçš„è² é¢å½±éŸ¿ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ä¾†æ¸›å°‘ç¥ç¶“ç´°èƒçš„å‡‹äº¡ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„ç ”ç©¶ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“ç´°èƒçš„å­˜æ´»æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼ç†è§£å¦‚ä½•æ¸›å°‘ç¥ç¶“ç´°èƒæ­»äº¡ã€æ”¹å–„ç¥ç¶“å¥åº·å…·æœ‰æ½›åœ¨æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘æ¢ç´¢æ–°çš„é é˜²æˆ–æ²»ç™‚æ–¹æ³•ï¼Œç‰¹åˆ¥æ˜¯é‡å°èˆ‡è€åŒ–ç›¸é—œçš„ç–¾ç—…ï¼Œå¦‚é˜¿èŒ²ç½•é»˜ç—‡ç­‰ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ–¼é˜¿Î²42æ¿€æ´»çš„æ˜Ÿç‹€è† ç´°èƒæ‰€å¼•èµ·çš„ç¥ç¶“ç´°èƒå‡‹äº¡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æ˜Ÿç‹€è† ç´°èƒå’Œç¥ç¶“ç´°èƒä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨é€™ç¨®ç›¸äº’ä½œç”¨å°ç¥ç¶“ç´°èƒå­˜æ´»çš„å½±éŸ¿ã€‚é€™å°æ–¼ç†è§£ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42å’Œè˜¿è””ç¡«ç´ ä¾†è™•ç†U87æ˜Ÿç‹€è† ç´°èƒï¼Œä¸¦è§€å¯Ÿç´°èƒæ´»æ€§åŠç›¸é—œè›‹ç™½è³ªå’ŒåŸºå› è¡¨é”çš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„å°‡SH-SY5Yç¥ç¶“ç´°èƒèˆ‡è™•ç†éé˜¿Î²42çš„U87æ˜Ÿç‹€è† ç´°èƒå…±åŒåŸ¹é¤Šï¼Œä¸¦æª¢æ¸¬ç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡å’Œå‡‹äº¡ç›¸é—œè›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢æ˜Ÿç‹€è† ç´°èƒï¼Œé€²ä¸€æ­¥æ¢è¨é€™äº›ç´°èƒå°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87æ˜Ÿç‹€è† ç´°èƒæ¥å—é˜¿Î²42è™•ç†å¾Œï¼Œå…¶æ´»æ€§æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦ä¸”æœƒä¿ƒé€²å‡‹äº¡ç›¸é—œè›‹ç™½Baxçš„è¡¨é”ï¼Œå°è‡´SH-SY5Yç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡é™ä½ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†åœ¨ä¸€å®šæ¿ƒåº¦ä¸‹å°æ˜Ÿç‹€è† ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ï¼Œä½†èƒ½å¤ æ¸›å°‘é˜¿Î²42å°ç¥ç¶“ç´°èƒçš„è² é¢å½±éŸ¿ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ä¾†æ¸›å°‘ç¥ç¶“ç´°èƒçš„å‡‹äº¡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠNan fang yi ke da xue xue bao = Journal of Southern Medical Universityã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°æˆ‘å€‘çš„å¤§è…¦å¥åº·å¯èƒ½æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ æ€éº¼å½±éŸ¿ç¥ç¶“ç´°èƒçš„å­˜æ´»ï¼Œç‰¹åˆ¥æ˜¯åœ¨èˆ‡é˜¿èŒ²ç½•é»˜ç—‡ç­‰ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…æœ‰é—œçš„æƒ…æ³ä¸‹ã€‚ ç ”ç©¶è€…å€‘ç”¨ä¸åŒæ¿ƒåº¦çš„é˜¿Î²42ï¼ˆé€™æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´ç¥ç¶“ç´°èƒæ­»äº¡çš„è›‹ç™½è³ªï¼‰å’Œè˜¿è””ç¡«ç´ å°æ˜Ÿç‹€è† ç´°èƒé€²è¡Œè™•ç†ï¼Œç„¶å¾Œè§€å¯Ÿç´°èƒçš„æ´»æ€§å’ŒåŸºå› è¡¨é”çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œç•¶æ˜Ÿç‹€è† ç´°èƒå—åˆ°é˜¿Î²42å½±éŸ¿æ™‚ï¼Œæœƒä¿ƒé€²å‡‹äº¡ç›¸é—œè›‹ç™½çš„è¡¨é”ï¼Œé€™è®“ç¥ç¶“ç´°èƒçš„å­˜æ´»ç‡é™ä½ã€‚ä¸éï¼Œè˜¿è””ç¡«ç´ åœ¨ä¸€å®šæ¿ƒåº¦ä¸‹èƒ½æ¸›å°‘é˜¿Î²42å°ç¥ç¶“ç´°èƒçš„è² é¢å½±éŸ¿ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç´°èƒï¼ ä¾†çœ‹çœ‹é€™äº›é—œéµé»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç¥ç¶“ç´°èƒçš„å­˜æ´»ã€‚\n2. é˜¿Î²42æœƒå½±éŸ¿æ˜Ÿç‹€è† ç´°èƒï¼Œå°è‡´ç¥ç¶“ç´°èƒæ­»äº¡ã€‚\n3. è˜¿è””ç¡«ç´ æˆ–èƒ½æ¸›å°‘é˜¿Î²42çš„è² é¢å½±éŸ¿ï¼Œä¿è­·ç¥ç¶“ç´°èƒã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of the study on sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate the experimental steps, and a section highlighting the main results (such as protective effects or changes observed).",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é˜¿èŒ²ç½•é»˜ç—‡ Alzheimer's Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41540706/"
  },
  {
    "id": "41565088",
    "title_en": "Sulforaphane attenuates HFD-induced enteritis in yellow river carp by restoring immune homeostasis, repairing intestinal barrier, and modulating gut microbiota.",
    "pub_date": "2026 Jan",
    "journal": "Fish & shellfish immunology",
    "abstract_en": "High-fat diets (HFD) exacerbate intestinal health risks in aquaculture. This study evaluated effects of dietary sulforaphane (SFN) supplementation on intestinal morphology, biochemistry, microbiota, and metabolism in Yellow River carp (Cyprinus carpio haematopterus) fed HFD. Five isoprotein diets diets were formulated: control (CN, 6Â % lipid), HFD (12.29Â % lipid), and HFD with 10 (HS10), 15 (HS15), or 20 (HS20) mg/kg SFN. Results demonstrated that HFD induced marked intestinal inflammation featuring villi deformation, oxidative stress, epithelial exfoliation, mitochondrial swelling, significantly elevated pro-inflammatory cytokines (TNF-Î±/IL-1Î²/IL-6; pÂ <Â 0.05), and downregulated tight junction protein genes (Occludin/ZO-1/Claudin-3; pÂ <Â 0.05), concomitant with microbial dysbiosis (Proteobacteria dominance>70Â %, reduced Cetobacterium) and disrupted metabolic pathways (amino acid imbalance). SFN supplementation significantly enhanced antioxidant enzyme activities (SOD/CAT/GSH-Px, pÂ <Â 0.05), peaking in HS15, which also exhibited minimized pro-inflammatory cytokines and maximized tight junction expression (pÂ <Â 0.05). Furthermore, 16S rRNA gene sequencing of the gut microbiota indicated that SFN restored microbial homeostasis, notably by increasing the abundance of Cetobacterium. Metabolomic analysis based on KEGG enrichment revealed that these beneficial effects were associated with the activation of FoxO signaling, enhanced lysosomal function, and upregulation of coenzyme A biosynthesis. Critically, HS15 demonstrated optimal efficacy across all parameters. Therefore, 15Â mg/kg SFN is identified as the optimal dose to ameliorate intestinal health in Yellow River carp, providing a theoretical basis for functional aquafeed development.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£Ÿå¯èƒ½æœƒå°é­šé¡çš„è…¸é“å¥åº·é€ æˆè² é¢å½±éŸ¿ï¼Œå°è‡´è…¸é“ç™¼ç‚å’Œå¾®ç”Ÿç‰©å¤±è¡¡ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶é¡¯ç¤ºå¯ä»¥æ”¹å–„é€™äº›å•é¡Œï¼Œé€™å°æ–¼é¤Šæ®–æ¥­è€…ä¾†èªªï¼Œå¯èƒ½æ„å‘³è‘—é€éèª¿æ•´é£¼æ–™æˆåˆ†ä¾†æå‡é­šé¡çš„å¥åº·ç‹€æ³ï¼Œé€²è€Œæé«˜é¤Šæ®–æ•ˆç‡å’Œç”¢å“å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é«˜è„‚é£²é£Ÿä¸‹çš„é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶é€™äº›é­šé¡æ”å–é«˜è„‚é£²é£Ÿæ™‚ï¼Œè…¸é“çš„çµæ§‹å’ŒåŠŸèƒ½æœƒå—åˆ°ä»€éº¼æ¨£çš„å½±éŸ¿ï¼Œä»¥åŠè£œå……è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼æ°´ç”¢é¤Šæ®–çš„å¯æŒçºŒç™¼å±•å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„é£¼æ–™é…æ–¹ï¼ŒåŒ…æ‹¬å°ç…§çµ„ï¼ˆ6%è„‚è‚ªï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆ12.29%è„‚è‚ªï¼‰ä»¥åŠä¸‰ç¨®ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ è£œå……çµ„ï¼ˆ10ã€15å’Œ20 mg/kgï¼‰ã€‚ç ”ç©¶å°è±¡æ˜¯é»ƒæ²³é¯‰é­šï¼Œé€šéè§€å¯Ÿå…¶è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆå’Œä»£è¬æƒ…æ³ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…å…¨é¢äº†è§£è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç™¼ç‚ã€æ°§åŒ–å£“åŠ›å¢åŠ å’Œå¾®ç”Ÿç‰©å¤±è¡¡ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ã€‚ç‰¹åˆ¥æ˜¯15 mg/kgçš„åŠ‘é‡åœ¨å„é …æŒ‡æ¨™ä¸Šè¡¨ç¾æœ€ä½³ï¼Œèƒ½æœ‰æ•ˆæé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ç™¼ç‚å› å­ï¼Œä¸¦ä¿ƒé€²è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œå¾®ç”Ÿç‰©çµ„çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›çµæœç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ°´ç”¢é¤Šæ®–é ˜åŸŸã€‚é«˜è„‚é£²é£Ÿå¯èƒ½æœƒå°é­šé¡çš„è…¸é“å¥åº·é€ æˆè² é¢å½±éŸ¿ï¼Œå°è‡´è…¸é“ç™¼ç‚å’Œå¾®ç”Ÿç‰©å¤±è¡¡ã€‚é€éè£œå……è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶é¡¯ç¤ºå¯ä»¥æ”¹å–„é€™äº›å•é¡Œï¼Œé€™å°æ–¼é¤Šæ®–æ¥­è€…ä¾†èªªï¼Œå¯èƒ½æ„å‘³è‘—é€éèª¿æ•´é£¼æ–™æˆåˆ†ä¾†æå‡é­šé¡çš„å¥åº·ç‹€æ³ï¼Œé€²è€Œæé«˜é¤Šæ®–æ•ˆç‡å’Œç”¢å“å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é«˜è„‚é£²é£Ÿä¸‹çš„é»ƒæ²³é¯‰é­šè…¸é“å¥åº·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç•¶é€™äº›é­šé¡æ”å–é«˜è„‚é£²é£Ÿæ™‚ï¼Œè…¸é“çš„çµæ§‹å’ŒåŠŸèƒ½æœƒå—åˆ°ä»€éº¼æ¨£çš„å½±éŸ¿ï¼Œä»¥åŠè£œå……è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼æ°´ç”¢é¤Šæ®–çš„å¯æŒçºŒç™¼å±•å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„é£¼æ–™é…æ–¹ï¼ŒåŒ…æ‹¬å°ç…§çµ„ï¼ˆ6%è„‚è‚ªï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆ12.29%è„‚è‚ªï¼‰ä»¥åŠä¸‰ç¨®ä¸åŒåŠ‘é‡çš„è˜¿è””ç¡«ç´ è£œå……çµ„ï¼ˆ10ã€15å’Œ20 mg/kgï¼‰ã€‚ç ”ç©¶å°è±¡æ˜¯é»ƒæ²³é¯‰é­šï¼Œé€šéè§€å¯Ÿå…¶è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆå’Œä»£è¬æƒ…æ³ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…å…¨é¢äº†è§£è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå°è‡´è…¸é“ç™¼ç‚ã€æ°§åŒ–å£“åŠ›å¢åŠ å’Œå¾®ç”Ÿç‰©å¤±è¡¡ï¼Œè€Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½é¡¯è‘—æ”¹å–„é€™äº›æƒ…æ³ã€‚ç‰¹åˆ¥æ˜¯15 mg/kgçš„åŠ‘é‡åœ¨å„é …æŒ‡æ¨™ä¸Šè¡¨ç¾æœ€ä½³ï¼Œèƒ½æœ‰æ•ˆæé«˜æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œæ¸›å°‘ç™¼ç‚å› å­ï¼Œä¸¦ä¿ƒé€²è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œå¾®ç”Ÿç‰©çµ„çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›çµæœç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFish & shellfish immunologyã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é­šå…’ä¹Ÿéœ€è¦å¥åº·çš„è…¸é“ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°é­šé¡è…¸é“å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨é«˜è„‚é£²é£Ÿçš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œç•¶é­šé¡åƒäº†é«˜è„‚è‚ªçš„é£¼æ–™ï¼Œè…¸é“å¥åº·å°±æœƒå—åˆ°å½±éŸ¿ï¼Œå¯èƒ½æœƒå‡ºç¾ç™¼ç‚å’Œå¾®ç”Ÿç‰©å¤±è¡¡çš„å•é¡Œã€‚ç‚ºäº†è§£æ±ºé€™å€‹å•é¡Œï¼Œä»–å€‘åœ¨å¯¦é©—ä¸­çµ¦é­šé¡è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹æ˜¯å¦èƒ½æ”¹å–„é€™äº›æƒ…æ³ã€‚ ç ”ç©¶ä¸­ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„é£¼æ–™é…æ–¹ï¼Œä¸¦è§€å¯Ÿé­šé¡çš„è…¸é“å½¢æ…‹å’Œå¾®ç”Ÿç‰©çµ„æˆã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½é¡¯è‘—æ”¹å–„è…¸é“å¥åº·ï¼Œå°¤å…¶æ˜¯15 mg/kgçš„åŠ‘é‡æ•ˆæœæœ€ä½³ï¼é€™ä¸åƒ…èƒ½æé«˜é­šé¡çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œé‚„èƒ½æ¢å¾©è…¸é“å¾®ç”Ÿç‰©çš„å¹³è¡¡ã€‚é€™äº›ç™¼ç¾å°æ–¼æœªä¾†çš„æ°´ç”¢é¤Šæ®–æ¥­æœ‰è‘—é‡è¦çš„æ„ç¾©ï¼ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š 1. é«˜è„‚é£²é£Ÿæœƒå½±éŸ¿é­šé¡çš„è…¸é“å¥åº·ã€‚ 2. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“ç‚ç—‡å’Œå¾®ç”Ÿç‰©å¤±è¡¡ã€‚ 3. 15 mg/kgçš„åŠ‘é‡æ•ˆæœæœ€ä½³ï¼",
    "image_prompt": "Create an infographic that explains the research on the effects of sulforaphane on fish gut health. Include symbols for broccoli or sulforaphane, simplified illustrations of fish, and arrows showing the experimental steps. Highlight a section labeled 'Key Findings' that summarizes the protective effects and changes observed in the gut health of the fish.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“å¥åº· Intestinal Health",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41565088/"
  },
  {
    "id": "41535692",
    "title_en": "Inhibiting autophagy enhances anti-cancer properties of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Scientific reports",
    "abstract_en": "Bladder cancer (BC) has an extremely low survival rate due to its tendency to metastasize. The antimalarial drug chloroquine (CQ) can inhibit BC progression and invasiveness by targeting basal autophagy. However, the mechanism by which CQ affects BC is not defined. Here, we revealed that although CQ showed an anticancer effect by reducing the migration and proliferation of the analyzed bladder cancer cells, it increased the expression of ICAM-1, a protein whose expression is associated with higher tumorigenic potential. Sulforaphane (SFN), a well-known ICAM-1 inhibitor, significantly contributed to the enhancement of anticancer effect of CQ, through regulation of both AKT/GSK-3Î² and mTOR/ULK pathways, which led to effective inhibition of autophagy, reduced proliferation level or inhibition of migration of the analyzed bladder cells. Moreover, regulation of pathways related to autophagy contributed to the reduction of mitochondrial membrane potential and regulation of ROS level. Nevertheless, the level of influence of CQ and SFN on the anticancer effects strongly depended on the molecular basis of the analyzed bladder cell lines. Our data indicate that although CQ exerts antitumor effects on bladder cancer cells, it should be noted that activation of some pro-tumor pathways may be associated with subsequent disease relapse or treatment resistance.",
    "para1": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è†€èƒ±ç™Œçš„æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢é•·çš„åŒæ™‚ï¼Œä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤ç™¼å±•ç›¸é—œçš„é€”å¾‘ã€‚å› æ­¤ï¼Œäº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æ”¹å–„æ²»ç™‚æ•ˆæœå’Œé™ä½å¾©ç™¼é¢¨éšªéå¸¸é‡è¦ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·å’Œé·ç§»ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹åœ¨æŠ—ç™Œéç¨‹ä¸­å¯èƒ½æ¿€æ´»çš„æŸäº›è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªå¯èƒ½æœƒå½±éŸ¿è…«ç˜¤çš„ç™¼å±•æ½›åŠ›ã€‚é€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼æ­ç¤ºè—¥ç‰©çš„é›™é¢æ€§ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›åƒè€ƒã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†è©•ä¼°ç´°èƒçš„é·ç§»å’Œå¢æ®–æƒ…æ³ï¼Œä¸¦æª¢æ¸¬äº†èˆ‡è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ·±å…¥äº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ä¸€ç¨®åç‚ºICAM-1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™èˆ‡è…«ç˜¤çš„æ½›åœ¨ç™¼å±•æœ‰é—œã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€šéèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‡ªå™¬å’Œé™ä½ç´°èƒå¢æ®–ã€‚ä¸éï¼Œé€™äº›è—¥ç‰©çš„æ•ˆæœæœƒå—åˆ°ä¸åŒè†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤æœªä¾†çš„ç ”ç©¶éœ€è¦é€²ä¸€æ­¥æ¢è¨é€™äº›æ©Ÿåˆ¶ã€‚",
    "explanation_zh": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è†€èƒ±ç™Œçš„æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›è—¥ç‰©å¯èƒ½åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢é•·çš„åŒæ™‚ï¼Œä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤ç™¼å±•ç›¸é—œçš„é€”å¾‘ã€‚å› æ­¤ï¼Œäº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æ”¹å–„æ²»ç™‚æ•ˆæœå’Œé™ä½å¾©ç™¼é¢¨éšªéå¸¸é‡è¦ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æŠ—ç˜§ç–¾è—¥ç‰©æ°¯å–¹ï¼ˆCQï¼‰å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·å’Œé·ç§»ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹åœ¨æŠ—ç™Œéç¨‹ä¸­å¯èƒ½æ¿€æ´»çš„æŸäº›è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªå¯èƒ½æœƒå½±éŸ¿è…«ç˜¤çš„ç™¼å±•æ½›åŠ›ã€‚é€™æ¨£çš„ç ”ç©¶æœ‰åŠ©æ–¼æ­ç¤ºè—¥ç‰©çš„é›™é¢æ€§ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›åƒè€ƒã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†è©•ä¼°ç´°èƒçš„é·ç§»å’Œå¢æ®–æƒ…æ³ï¼Œä¸¦æª¢æ¸¬äº†èˆ‡è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ·±å…¥äº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹èƒ½å¤ æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†åŒæ™‚ä¹Ÿæœƒå¢åŠ ä¸€ç¨®åç‚ºICAM-1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™èˆ‡è…«ç˜¤çš„æ½›åœ¨ç™¼å±•æœ‰é—œã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œé€šéèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‡ªå™¬å’Œé™ä½ç´°èƒå¢æ®–ã€‚ä¸éï¼Œé€™äº›è—¥ç‰©çš„æ•ˆæœæœƒå—åˆ°ä¸åŒè†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤å½±éŸ¿ï¼Œå› æ­¤æœªä¾†çš„ç ”ç©¶éœ€è¦é€²ä¸€æ­¥æ¢è¨é€™äº›æ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠScientific reportsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ è†€èƒ±ç™Œçš„ç ”ç©¶æ–°é€²å±•ï¼ä½ çŸ¥é“å—ï¼Ÿé€™ç¨®ç™Œç—‡çš„å­˜æ´»ç‡å¾ˆä½ï¼Œå› ç‚ºå®ƒå¾ˆå®¹æ˜“è½‰ç§»ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°æŠ—è†€èƒ±ç™Œçš„æ²»ç™‚æ–¹æ³•æœ‰äº†æ–°çš„ç†è§£ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨ä¸€ç¨®æŠ—ç˜§ç–¾è—¥ç‰©å«åšæ°¯å–¹ï¼ˆCQï¼‰ï¼Œå®ƒå°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œæ°¯å–¹ä¸åƒ…èƒ½æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œé‚„å¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤ç™¼å±•æœ‰é—œçš„è›‹ç™½è³ªï¼Œé€™è®“æˆ‘å€‘å°è—¥ç‰©çš„é›™é¢æ€§æœ‰äº†æ–°çš„èªè­˜ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ä½¿ç”¨å¤šç¨®æ–¹æ³•ä¾†è©•ä¼°ç´°èƒçš„é·ç§»å’Œå¢æ®–æƒ…æ³ï¼Œä¸¦æª¢æ¸¬äº†èˆ‡ç´°èƒè‡ªå™¬ï¼ˆç´°èƒè‡ªæˆ‘æ¸…ç†ï¼‰ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ°¯å–¹èƒ½æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†å»æœƒå¢åŠ ä¸€ç¨®åç‚ºICAM-1çš„è›‹ç™½è³ªï¼Œé€™èˆ‡è…«ç˜¤çš„æ½›åœ¨ç™¼å±•æœ‰é—œã€‚è€Œè˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœã€‚\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. æ°¯å–¹èƒ½æ¸›å°‘è†€èƒ±ç™Œç´°èƒçš„å¢é•·ï¼Œä½†å¯èƒ½æœ‰å‰¯ä½œç”¨ã€‚\n2. è˜¿è””ç¡«ç´ å¯ä»¥å¢å¼·æ°¯å–¹çš„æ•ˆæœï¼Œå¹«åŠ©æŠ‘åˆ¶ç™Œç´°èƒã€‚\n3. ä¸åŒçš„è†€èƒ±ç™Œç´°èƒæœ‰ä¸åŒçš„åæ‡‰ï¼Œæœªä¾†é‚„éœ€è¦æ›´å¤šç ”ç©¶ï¼",
    "image_prompt": "Create a flat infographic that explains the experimental methods and main findings of a study on bladder cancer. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results such as protective effects or changes observed. Use a light background with soft colors and a clear, educational style.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è†€èƒ±ç™Œ Bladder Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41535692/"
  },
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚ï¼Œä¸¦é€²ä¸€æ­¥ä¿ƒé€²è…¸é“å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èˆ‡è…¸é“å¥åº·ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é‡è¦çš„è›‹ç™½è³ªã€‚é€™äº›è›‹ç™½è³ªåœ¨èª¿ç¯€èº«é«”çš„æŠ—æ°§åŒ–åæ‡‰å’Œç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„è®ŠåŒ–å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„ç ”ç©¶è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨é”é™ä½ï¼Œè€ŒSTAT3çš„è¡¨é”å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œé€éè½‰æŸ“Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œä»–å€‘é‚„åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­æ¸¬è©¦äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè§€å¯Ÿå…¶å°è…¸é“ç—‡ç‹€çš„æ”¹å–„æƒ…æ³ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦çš„è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œä¸é©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„æ²»ç™‚ï¼Œä¸¦é€²ä¸€æ­¥ä¿ƒé€²è…¸é“å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èˆ‡è…¸é“å¥åº·ç›¸é—œçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œç‰¹åˆ¥æ˜¯Nrf2å’ŒSTAT3é€™å…©å€‹é‡è¦çš„è›‹ç™½è³ªã€‚é€™äº›è›‹ç™½è³ªåœ¨èª¿ç¯€èº«é«”çš„æŠ—æ°§åŒ–åæ‡‰å’Œç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„è®ŠåŒ–å°æ–¼æ½°ç˜æ€§çµè…¸ç‚çš„ç ”ç©¶è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚é¦–å…ˆï¼Œä»–å€‘åˆ†æäº†æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç™¼ç¾Nrf2çš„è¡¨é”é™ä½ï¼Œè€ŒSTAT3çš„è¡¨é”å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨DSSèª˜å°çš„Caco-2ç´°èƒæ¨¡å‹ä¸­é€²è¡Œäº†å¯¦é©—ï¼Œé€éè½‰æŸ“Nrf2çš„siRNAä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œä»–å€‘é‚„åœ¨DSSèª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä¸­æ¸¬è©¦äº†è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œè§€å¯Ÿå…¶å°è…¸é“ç—‡ç‹€çš„æ”¹å–„æƒ…æ³ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç´°èƒæµ¸æ½¤ç­‰ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ç‚ç—‡ç´°èƒå› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨ç¼ºä¹Nrf2çš„å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦çš„è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯é¤æ¡Œä¸Šçš„ç¾å‘³ï¼Œé‚„å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©å“¦ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†ï¼Œå¯èƒ½å°æ–¼æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€æœ‰ä¸€å®šçš„ä½œç”¨ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®è®“äººæ„Ÿåˆ°ä¸é©çš„è…¸é“ç–¾ç—…ï¼Œç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ”¹å–„é€™ç¨®æƒ…æ³ã€‚  \n  \nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†å°é¼ å’Œç´°èƒæ¨¡å‹ä¾†é€²è¡Œå¯¦é©—ã€‚ä»–å€‘ç™¼ç¾ï¼Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ä¸­ï¼Œæœ‰ä¸€ç¨®å«Nrf2çš„è›‹ç™½è³ªè¡¨ç¾é™ä½ï¼Œè€Œå¦ä¸€ç¨®å«STAT3çš„è›‹ç™½è³ªå‰‡è¡¨ç¾å‡é«˜ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…å€‘åœ¨å°é¼ èº«ä¸Šæ¸¬è©¦äº†è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒå°è…¸é“ç—‡ç‹€çš„å½±éŸ¿ã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å°é¼ çš„é«”é‡æ¸›è¼•ã€è…¸é“æ°´è…«å’Œç‚ç—‡ç­‰ç—‡ç‹€ï¼Œé‚„èƒ½é™ä½ç‚ç—‡å› å­çš„æ°´å¹³ï¼Œä¸¦å¢å¼·è…¸é“çš„ä¿è­·åŠŸèƒ½ã€‚ä¸éï¼Œç•¶ç¼ºä¹Nrf2çš„æƒ…æ³ä¸‹ï¼Œé€™äº›æ•ˆæœå°±æœƒå¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºå‡ºNrf2åœ¨é€™å€‹éç¨‹ä¸­çš„é‡è¦æ€§ã€‚  \n  \né€™äº›ç™¼ç¾ç‚ºæœªä¾†æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚  \n2. Nrf2å’ŒSTAT3åœ¨è…¸é“å¥åº·ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚  \n3. ç ”ç©¶çµæœç‚ºæœªä¾†æ²»ç™‚æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic illustrating the research on the effects of sulforaphane (found in broccoli and radishes) on ulcerative colitis. Include simplified icons of broccoli and radishes, as well as representations of experimental subjects like mice and cells. Use arrows or flow lines to show the experimental process, and include a section highlighting the main results, such as symptom relief and changes in protein levels. The background should be light-colored with a soft color palette, suitable for educational purposes.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41543290",
    "title_en": "Elucidation of Sulforaphane-Mediated Effects on the Cellular Human Metabolome Using Metabolic Profiling.",
    "pub_date": "2026 Jan",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from glucoraphanin, which occurs in broccoli. Several human health-promoting effects are attributed to the consumption of cruciferous vegetables or food supplements containing SFN. Its described cancer-preventive, chemoprotective, and antioxidant properties made SFN an increasingly important research topic. The antioxidant properties have previously been connected to stimulation of the Nuclear factor erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway. However, the global effects of SFN on the primary metabolic pathways have yet to be fully unraveled. Therefore metabolic profiling was used to elucidate the effects of SFN on the cellular metabolome. For this purpose, human hepatoblastoma cells (HepG2) were incubated with SFN and the changes of primary metabolite levels were determined by targeted hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC-MS/MS) analysis. Metabolic profiling revealed that SFN affects the tricarboxylic acid cycle, the urea cycle and their related amino acids. Furthermore, effects on glycolysis, pentose phosphate pathway and glutathione (GSH) levels were observed. This profound impact on nearly all primary metabolic pathways indicates a high bioactive potential of this natural compound. Especially elevated GSH levels underline the commonly described antioxidant potential of SFN.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰å¤šç¨®å¥½è™•ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨åå­—èŠ±ç§‘è”¬èœæˆ–å«æœ‰è˜¿è””ç¡«ç´ çš„é£Ÿå“è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯ç™Œç—‡ã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•è®“äººå€‘å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶å……æ»¿æœŸå¾…ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒæ–¹é¢çš„æ•ˆæœï¼Œé€™äº›éƒ½å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸»è¦ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨ç™Œç—‡é é˜²å’Œç´°èƒä¿è­·æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶ä¹‹å‰çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä½†å…¶å°ç´°èƒä»£è¬çš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€ç©ºç™½ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œæ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•èƒ½å¤ å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å…·é«”å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘å’Œè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„æ½›èƒ½ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨å¥åº·ä¿ƒé€²æ–¹é¢çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰å¤šç¨®å¥½è™•ã€‚è¨±å¤šç ”ç©¶æŒ‡å‡ºï¼Œé£Ÿç”¨åå­—èŠ±ç§‘è”¬èœæˆ–å«æœ‰è˜¿è””ç¡«ç´ çš„é£Ÿå“è£œå……åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯ç™Œç—‡ã€‚é€™äº›æ½›åœ¨çš„å¥åº·ç›Šè™•è®“äººå€‘å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶å……æ»¿æœŸå¾…ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’Œä¿è­·ç´°èƒæ–¹é¢çš„æ•ˆæœï¼Œé€™äº›éƒ½å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸»è¦ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨ç™Œç—‡é é˜²å’Œç´°èƒä¿è­·æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶ä¹‹å‰çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä½†å…¶å°ç´°èƒä»£è¬çš„å…¨é¢å½±éŸ¿ä»ç„¶ä¸å¤ æ¸…æ¥šï¼Œå› æ­¤é€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€ç©ºç™½ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œæ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™ç¨®æ–¹æ³•èƒ½å¤ å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å…·é«”å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘å’Œè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯æå‡çš„GSHæ°´å¹³é€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„æ½›èƒ½ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨å¥åº·ä¿ƒé€²æ–¹é¢çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼\n\né€™ç¯‡ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“é€™ç¨®æˆåˆ†å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¸»è¦ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é é˜²å’Œä¿è­·ç´°èƒæ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶ä¹‹å‰çš„ç ”ç©¶å·²ç¶“ç™¼ç¾äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œä½†å°å®ƒå°ç´°èƒä»£è¬çš„å…¨é¢å½±éŸ¿é‚„ä¸æ˜¯å¾ˆæ¸…æ¥šï¼Œæ‰€ä»¥é€™æ¬¡çš„ç ”ç©¶å°±æ˜¯è¦è§£ç­”é€™å€‹å•é¡Œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ï¼Œå°‡å®ƒå€‘èˆ‡è˜¿è””ç¡«ç´ ä¸€èµ·åŸ¹é¤Šï¼Œä¸¦åˆ©ç”¨ä¸€ç¨®ç‰¹æ®Šçš„åˆ†ææ–¹æ³•ä¾†æ¸¬é‡ç´°èƒå…§çš„ä»£è¬ç‰©è®ŠåŒ–ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°å’Œå°¿ç´ å¾ªç’°ç­‰ï¼Œé€™äº›éƒ½æ˜¯ç´°èƒèƒ½é‡å’Œæ’æ¯’çš„é‡è¦éç¨‹ã€‚\n\nç¸½çµä¾†èªªï¼Œé€™é …ç ”ç©¶ç™¼ç¾äº†ä»¥ä¸‹å¹¾é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æå‡ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n2. å®ƒå°ç´°èƒå…§çš„å¤šå€‹ä»£è¬é€”å¾‘æœ‰é¡¯è‘—å½±éŸ¿ã€‚\n3. é€²ä¸€æ­¥çš„ç ”ç©¶å¯èƒ½æœƒæ­ç¤ºå®ƒåœ¨ç™Œç—‡é é˜²ä¸­çš„æ½›åŠ›ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†æ›´å¤šæœ‰é—œè˜¿è””ç¡«ç´ çš„ç ”ç©¶å§ï¼",
    "image_prompt": "Create an informative infographic that explains the experiment and main results of the study on sulforaphane. The image should have a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or animal cells, and arrows or flow lines indicating the experimental steps. Also, have a section that clearly states the 'Main Results', highlighting protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41543290/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ²»ç™‚é€™ç¨®ç–¾ç—…ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ¢è¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶å£è…”ç™Œç´°èƒçš„é€²å±•ï¼Œä¸¦æ·±å…¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²çŸ¥å…·æœ‰æŸäº›æŠ—è…«ç˜¤ç‰¹æ€§ï¼Œä½†å…¶åœ¨å£è…”ç™Œä¸­çš„å…·é«”ä½œç”¨ä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶å¡«è£œäº†é€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬è©¦è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„å½±éŸ¿ï¼Œä»¥åŠä¿ƒé€²ç´°èƒå‡‹äº¡çš„èƒ½åŠ›ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦ä½¿ç”¨ç‰¹å®šçš„æŠ‘åˆ¶åŠ‘ä¾†äº†è§£ä¸åŒä¿¡è™Ÿé€šè·¯çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡c-Jun N-terminal kinaseï¼ˆJNKï¼‰é€šè·¯æœ‰é—œï¼Œé€™æ„å‘³è‘—JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„æŠ—ç™Œä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸­æ‡‰ç”¨å¤©ç„¶åŒ–åˆç‰©æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é¡¯ç¤ºå‡ºå°è…«ç˜¤çš„æŠ‘åˆ¶ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚å£è…”é±—ç‹€ç´°èƒç™Œçš„ä¸€å€‹æ½›åœ¨é¸æ“‡ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ²»ç™‚é€™ç¨®ç–¾ç—…ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œå¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ¢è¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶å£è…”ç™Œç´°èƒçš„é€²å±•ï¼Œä¸¦æ·±å…¥äº†è§£å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²çŸ¥å…·æœ‰æŸäº›æŠ—è…«ç˜¤ç‰¹æ€§ï¼Œä½†å…¶åœ¨å£è…”ç™Œä¸­çš„å…·é«”ä½œç”¨ä»ç„¶ä¸æ˜ï¼Œå› æ­¤é€™é …ç ”ç©¶å¡«è£œäº†é€™æ–¹é¢çš„çŸ¥è­˜ç©ºç™½ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬è©¦è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ã€ç´°èƒé€±æœŸçš„å½±éŸ¿ï¼Œä»¥åŠä¿ƒé€²ç´°èƒå‡‹äº¡çš„èƒ½åŠ›ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„æ¢è¨äº†èˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªèª¿æ§ç¨‹åºï¼Œä¸¦ä½¿ç”¨ç‰¹å®šçš„æŠ‘åˆ¶åŠ‘ä¾†äº†è§£ä¸åŒä¿¡è™Ÿé€šè·¯çš„ä½œç”¨ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶ä¸­ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡c-Jun N-terminal kinaseï¼ˆJNKï¼‰é€šè·¯æœ‰é—œï¼Œé€™æ„å‘³è‘—JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„æŠ—ç™Œä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸­æ‡‰ç”¨å¤©ç„¶åŒ–åˆç‰©æä¾›äº†å¯èƒ½çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ¿ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸è”¬èœè£¡ç«Ÿç„¶è—è‘—æŠ—ç™Œçš„æ½›åŠ›ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šå¯èƒ½æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸ï¼ˆSFN-Cysï¼‰å°å£è…”é±—ç‹€ç´°èƒç™Œçš„å½±éŸ¿ï¼Œç§‘å­¸å®¶å€‘æƒ³çŸ¥é“é€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œä¸¦ä¸”æ·±å…¥æ¢è¨å…¶èƒŒå¾Œçš„é‹ä½œæ©Ÿåˆ¶ã€‚é€éå¯¦é©—ï¼Œä»–å€‘ä½¿ç”¨äº†å£è…”ç™Œç´°èƒä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œä¸¦æ¸¬è©¦äº†å®ƒå°ç™Œç´°èƒçš„æ¯’æ€§ã€ç´°èƒé€±æœŸçš„å½±éŸ¿ä»¥åŠä¿ƒé€²ç´°èƒæ­»äº¡çš„èƒ½åŠ›ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -åŠèƒ±æ°¨é…¸èƒ½æœ‰æ•ˆåœ°èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä¸¦ä¸”é˜»æ­¢å…¶å¢é•·ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡ä¸€æ¢åç‚ºJNKçš„ä¿¡è™Ÿé€šè·¯æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å°æŠ—å£è…”ç™Œæä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼é é˜²å£è…”ç™Œã€‚\n2. ç ”ç©¶æ­ç¤ºäº†å…¶å°ç™Œç´°èƒçš„æ¯’æ€§å’Œä¿ƒé€²æ­»äº¡çš„èƒ½åŠ›ã€‚\n3. JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„æŠ—ç™Œä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on sulforaphane-cysteine (SFN-Cys) and its effects on oral squamous cell carcinoma (OSCC). Include simplified icons of broccoli or sulforaphane, human or cell figures as experimental subjects, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2026 Jan",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼Œé€™å°æ–¼å°‹æ±‚æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘æ¯’ç´ å½±éŸ¿çš„é£²é£Ÿç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™äº›ä¿è­·æ©Ÿåˆ¶ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²æªæ–½ï¼Œé™ä½é£Ÿç‰©ä¸­æ¯’çš„é¢¨éšªï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONçš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œæ²»ç™‚ã€‚æ­¤å¤–ï¼Œé‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œå¯¦é©—ï¼Œä»¥é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡åˆ†æå’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºç­‰æ–¹æ³•ä¾†ç ”ç©¶å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½å¯†åˆ‡ç›¸é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•DONå¼•èµ·çš„è…¸é“æå‚·æ–¹é¢æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºäº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é‡å¤§é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—é€™ç¨®æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼Œé€™å°æ–¼å°‹æ±‚æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘æ¯’ç´ å½±éŸ¿çš„é£²é£Ÿç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚äº†è§£é€™äº›ä¿è­·æ©Ÿåˆ¶ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²æªæ–½ï¼Œé™ä½é£Ÿç‰©ä¸­æ¯’çš„é¢¨éšªï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONçš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºå…©çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œæ²»ç™‚ã€‚æ­¤å¤–ï¼Œé‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œå¯¦é©—ï¼Œä»¥é€²ä¸€æ­¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡åˆ†æå’Œæµå¼ç´°èƒè¡“ï¼Œä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºç­‰æ–¹æ³•ä¾†ç ”ç©¶å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½å¯†åˆ‡ç›¸é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•DONå¼•èµ·çš„è…¸é“æå‚·æ–¹é¢æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºäº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶éš±è—è‘—ä¸€ç¨®å¯èƒ½å½±éŸ¿è…¸é“å¥åº·çš„æ¯’ç´ ï¼é€™å°±æ˜¯è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰ï¼Œå®ƒå­˜åœ¨æ–¼è¨±å¤šé£Ÿç‰©ä¸­ï¼Œå°æˆ‘å€‘çš„å¥åº·æ§‹æˆå¨è„…ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„ä¸€ç¨®æˆåˆ†â€”â€”è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å°æŠ—é€™ç¨®æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼\n\né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘ï¼Œä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œäº†å¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘DONå¼•èµ·çš„è…¸é“æå‚·ï¼Œé‚„èƒ½æ”¹å–„ç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œè®“è…¸é“åŠŸèƒ½æ¢å¾©å¾—æ›´å¥½ï¼\n\né€™äº›ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘äº†è§£äº†è˜¿è””ç¡«ç´ çš„å¥½è™•ï¼Œé‚„ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿæä¾›äº†æ–°çš„æ€è·¯ã€‚æƒ³çŸ¥é“æ›´è©³ç´°çš„çµæœå—ï¼Ÿ\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘è…¸é“æ¯’æ€§ã€‚\n2. æ”¹å–„è…¸é“çµæ§‹ï¼Œå¢å¼·è…¸é“åŠŸèƒ½ã€‚\n3. èˆ‡ç´°èƒçš„é…¸åŒ–åŠŸèƒ½æœ‰é—œï¼Œæä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of a study on the protective effects of sulforaphane against deoxynivalenol (DON) induced gut damage. Use a flat design style with a white or light-colored background and soft colors. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects such as mice and cells, and arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Findings' with simple descriptions of the protective effects observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•æå‡é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²ç–¾ç—…æ–¹é¢ã€‚é’èŠ±æ¤°èœå«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œå¯èƒ½èƒ½å¤ é€²ä¸€æ­¥å¢å¼·å…¶å°å¥åº·çš„æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†é é˜²ç–¾ç—…çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼Œä»¥æœŸé–‹ç™¼å‡ºæ›´å…·åŠŸèƒ½æ€§çš„é£Ÿå“ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†ä¸åŒçš„è™•ç†æ–¹æ³•ï¼Œä¸¦åœ¨å››å¤©å¾Œæ¸¬é‡é’èŠ±æ¤°èœèŠ½ä¸­çš„å„ç¨®ç‡Ÿé¤Šæˆåˆ†ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å…¶ä¿ç•™çš„ç‡Ÿé¤Šæˆåˆ†å’Œç‰©ç†ç‰¹æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”åœ¨æ°´åˆ†ä¿æŒèƒ½åŠ›ã€æ²¹åˆ†ä¿æŒèƒ½åŠ›å’Œè†¨è„¹èƒ½åŠ›æ–¹é¢ä¹Ÿé”åˆ°æœ€ä½³æ•ˆæœã€‚æ­¤å¤–ï¼Œæå–çš„è˜¿è””ç¡«ç´ å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå±•ç¾äº†é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•æå‡é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²ç–¾ç—…æ–¹é¢ã€‚é’èŠ±æ¤°èœå«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œå¯èƒ½èƒ½å¤ é€²ä¸€æ­¥å¢å¼·å…¶å°å¥åº·çš„æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†é é˜²ç–¾ç—…çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›è™•ç†æ–¹æ³•å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªï¼Œä»¥æœŸé–‹ç™¼å‡ºæ›´å…·åŠŸèƒ½æ€§çš„é£Ÿå“ã€‚\n\nç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­ä½¿ç”¨äº†ä¸åŒçš„è™•ç†æ–¹æ³•ï¼Œä¸¦åœ¨å››å¤©å¾Œæ¸¬é‡é’èŠ±æ¤°èœèŠ½ä¸­çš„å„ç¨®ç‡Ÿé¤Šæˆåˆ†ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å…¶ä¿ç•™çš„ç‡Ÿé¤Šæˆåˆ†å’Œç‰©ç†ç‰¹æ€§ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦ä¸”åœ¨æ°´åˆ†ä¿æŒèƒ½åŠ›ã€æ²¹åˆ†ä¿æŒèƒ½åŠ›å’Œè†¨è„¹èƒ½åŠ›æ–¹é¢ä¹Ÿé”åˆ°æœ€ä½³æ•ˆæœã€‚æ­¤å¤–ï¼Œæå–çš„è˜¿è””ç¡«ç´ å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå±•ç¾äº†é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·å¤§æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ­ç¤ºäº†å¦‚ä½•æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œç‰¹åˆ¥æ˜¯å®ƒè£¡é¢çš„è˜¿è””ç¡«ç´ ï¼é€™ç¨®æˆåˆ†è¢«èªç‚ºèƒ½å¢å¼·æˆ‘å€‘çš„å…ç–«ç³»çµ±ï¼Œç”šè‡³æœ‰æŠ—èŒçš„æ•ˆæœã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ä¸€ç¨®å«ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„è™•ç†æ–¹æ³•ï¼Œçœ‹çœ‹å®ƒå€‘å¦‚ä½•å½±éŸ¿é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ã€‚ç ”ç©¶è€…å€‘åœ¨å¯¦é©—ä¸­è§€å¯Ÿäº†ä¸åŒè™•ç†ä¸‹çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†è˜¿è””ç¡«ç´ å’Œå…¶ä»–é‡è¦æˆåˆ†çš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè”—ç³–çš„è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚è€Œç¶“éçœŸç©ºå†·å‡ä¹¾ç‡¥è™•ç†çš„é’èŠ±æ¤°èœèŠ½ç²‰ï¼Œé‚„èƒ½å¾ˆå¥½åœ°ä¿ç•™é€™äº›ç‡Ÿé¤Šæˆåˆ†ï¼Œä¸¦å±•ç¾å‡ºä¸éŒ¯çš„æŠ—èŒæ´»æ€§ã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è”—ç³–è™•ç†èƒ½æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥èƒ½æœ‰æ•ˆä¿ç•™è˜¿è””ç¡«ç´ ç­‰æˆåˆ†ã€‚\n3. è˜¿è””ç¡«ç´ å°æŠ—èŒæœ‰æ½›åœ¨æ•ˆæœï¼Œè®“æˆ‘å€‘çš„é£²é£Ÿæ›´å¥åº·ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on broccoli sprouts. The design should be flat and simple, with a white or light background and soft colors. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines to indicate the steps of the experiment, and a section that highlights the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›çš„å¢åŠ ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å‘¼å¸é“çš„ç™¼ç‚åæ‡‰ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…æ˜¯éå¸¸æœ‰æ„ç¾©çš„ã€‚é€™äº›å¤©ç„¶æˆåˆ†çš„æ½›åœ¨ç›Šè™•ï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„å¥åº·ç®¡ç†æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ï¼Œå°¤å…¶æ˜¯å¦‚ä½•åˆ©ç”¨é£Ÿç‰©ä¸­çš„å¤©ç„¶æˆåˆ†ä¾†å¢å¼·æˆ‘å€‘çš„å…ç–«ç³»çµ±å’ŒæŠµæŠ—åŠ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šã€‚é€™äº›æˆåˆ†çš„ç›¸äº’ä½œç”¨å¯èƒ½å°å‘¼å¸ç³»çµ±çš„å¥åº·æœ‰é‡è¦å½±éŸ¿ï¼Œå› æ­¤ç ”ç©¶çš„ç›®çš„åœ¨æ–¼æ·±å…¥äº†è§£å®ƒå€‘çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­é‚„æ¸¬é‡äº†ä¸åŒæ¿ƒåº¦ä¸‹çš„ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„æ¯’æ€§åæ‡‰ï¼Œé€™æ¨£çš„è¨­è¨ˆå¯ä»¥å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ç¨‹åº¦ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚é›–ç„¶é€™äº›ç™¼ç¾ä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›æˆåˆ†çš„å…·é«”æ•ˆæœåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»å£“åŠ›çš„å¢åŠ ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å‘¼å¸é“çš„ç™¼ç‚åæ‡‰ï¼Œé€™å°æ–¼é é˜²èˆ‡å‘¼å¸ç³»çµ±ç›¸é—œçš„ç–¾ç—…æ˜¯éå¸¸æœ‰æ„ç¾©çš„ã€‚é€™äº›å¤©ç„¶æˆåˆ†çš„æ½›åœ¨ç›Šè™•ï¼Œè®“æˆ‘å€‘å°æœªä¾†çš„å¥åº·ç®¡ç†æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ï¼Œå°¤å…¶æ˜¯å¦‚ä½•åˆ©ç”¨é£Ÿç‰©ä¸­çš„å¤©ç„¶æˆåˆ†ä¾†å¢å¼·æˆ‘å€‘çš„å…ç–«ç³»çµ±å’ŒæŠµæŠ—åŠ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šã€‚é€™äº›æˆåˆ†çš„ç›¸äº’ä½œç”¨å¯èƒ½å°å‘¼å¸ç³»çµ±çš„å¥åº·æœ‰é‡è¦å½±éŸ¿ï¼Œå› æ­¤ç ”ç©¶çš„ç›®çš„åœ¨æ–¼æ·±å…¥äº†è§£å®ƒå€‘çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•ï¼ˆHPLCï¼‰é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶ä¸­é‚„æ¸¬é‡äº†ä¸åŒæ¿ƒåº¦ä¸‹çš„ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„æ¯’æ€§åæ‡‰ï¼Œé€™æ¨£çš„è¨­è¨ˆå¯ä»¥å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ç¨‹åº¦ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚é›–ç„¶é€™äº›ç™¼ç¾ä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›æˆåˆ†çš„å…·é«”æ•ˆæœåŠå…¶åœ¨è‡¨åºŠä¸Šçš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯é¤æ¡Œä¸Šçš„é…èœï¼Œå®ƒé‚„å¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œæ¢è¨å®ƒå€‘å°æˆ‘å€‘çš„å‘¼å¸é“ç´°èƒæœ‰ä»€éº¼å½±éŸ¿ã€‚\n\nç ”ç©¶è€…ä½¿ç”¨äº†ä¸€äº›äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼Œæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œæƒ³äº†è§£é€™äº›å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ¸›å°‘ç´°èƒçš„ç™¼ç‚åæ‡‰ï¼Œä¸¦æå‡ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½ä¸€ç¨®åç‚ºIL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé€™å°æˆ‘å€‘çš„å¥åº·ç›¸ç•¶é‡è¦ï¼\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´æœ‰ä¿¡å¿ƒå»æ¢ç´¢å¦‚ä½•åˆ©ç”¨é£Ÿç‰©ä¾†å¢å¼·å…ç–«åŠ›ã€‚é›–ç„¶ç›®å‰çš„çµæœä»¤äººæŒ¯å¥®ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›æˆåˆ†çš„å…·é«”æ•ˆæœã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å‘¼å¸é“çš„ç™¼ç‚ã€‚\n2. å®ƒå€‘å¯ä»¥æé«˜ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. é€™äº›å¤©ç„¶æˆåˆ†åœ¨å¥åº·ç®¡ç†ä¸Šæœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of a study on the effects of daikon sulforaphane and black radish juice on human bronchial epithelial cells. Use a flat design style with a white or light-colored background and soft color palette. Include simplified illustrations of daikon or radish, human or cell figures as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' showing protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸ç³»çµ±ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰å’Œæ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„æ²»ç™‚æ–¹é¢ã€‚é€™äº›ç–¾ç—…é€šå¸¸æœƒå°è‡´è…¸é“æŒçºŒç™¼ç‚ï¼Œä¸¦ä¸”ç›®å‰å°šç„¡æ ¹æ²»çš„æ–¹æ³•ã€‚é›–ç„¶ç¾æœ‰çš„æ²»ç™‚å¯ä»¥æ§åˆ¶ç—‡ç‹€ï¼Œä½†å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªè‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†ä¾†è‡ªè¿·è¿­é¦™çš„åŒ–åˆç‰©å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸ï¼ˆCAï¼‰å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ½›åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯é€™äº›å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘èˆ‡ç‚ç—‡ç›¸é—œçš„æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²ç´°èƒå…§çš„æŠ—ç‚è·¯å¾‘æ´»æ€§ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„è¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„ç—‡ç‹€éå¸¸é‡è¦ï¼Œå°¤å…¶æ˜¯åœ¨ç›®å‰çš„æ²»ç™‚é¸æ“‡ä¸­å­˜åœ¨å‰¯ä½œç”¨çš„æƒ…æ³ä¸‹ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬è…¸é“ä¸Šçš®çµ„ç¹”çš„ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ï¼Œæä¾›äº†ä¸€å€‹ç”Ÿç†ç›¸é—œçš„ç’°å¢ƒä¾†è©•ä¼°é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´çœŸå¯¦åœ°åæ˜ è…¸é“ä¸­çš„æ°§æ°£æ°´å¹³ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°ç‚ç—‡ç´°èƒå› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬åŒ–å­¸å› å­æª¢æ¸¬å’ŒåŸºå› è¡¨é”åˆ†æã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—ç‚æœ‰é—œçš„é—œéµè·¯å¾‘ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBè·¯å¾‘ä¸‹ä¿ƒé€²æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™åœ¨ç‚ç—‡çš„è…¸é“ä¸Šçš®ä¸­è¡¨ç¾è¼ƒé«˜ï¼Œä¸¦è¢«å»ºè­°ä½œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†ä½¿ç”¨è…¸é“é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºCAå’ŒSFNåœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰å’Œæ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„æ²»ç™‚æ–¹é¢ã€‚é€™äº›ç–¾ç—…é€šå¸¸æœƒå°è‡´è…¸é“æŒçºŒç™¼ç‚ï¼Œä¸¦ä¸”ç›®å‰å°šç„¡æ ¹æ²»çš„æ–¹æ³•ã€‚é›–ç„¶ç¾æœ‰çš„æ²»ç™‚å¯ä»¥æ§åˆ¶ç—‡ç‹€ï¼Œä½†å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„ç™‚æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„é¸æ“‡ï¼Œå°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªè‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†ä¾†è‡ªè¿·è¿­é¦™çš„åŒ–åˆç‰©å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸ï¼ˆCAï¼‰å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ½›åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯é€™äº›å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘èˆ‡ç‚ç—‡ç›¸é—œçš„æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²ç´°èƒå…§çš„æŠ—ç‚è·¯å¾‘æ´»æ€§ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„è¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„ç—‡ç‹€éå¸¸é‡è¦ï¼Œå°¤å…¶æ˜¯åœ¨ç›®å‰çš„æ²»ç™‚é¸æ“‡ä¸­å­˜åœ¨å‰¯ä½œç”¨çš„æƒ…æ³ä¸‹ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬è…¸é“ä¸Šçš®çµ„ç¹”çš„ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ï¼Œæä¾›äº†ä¸€å€‹ç”Ÿç†ç›¸é—œçš„ç’°å¢ƒä¾†è©•ä¼°é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´çœŸå¯¦åœ°åæ˜ è…¸é“ä¸­çš„æ°§æ°£æ°´å¹³ã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°ç‚ç—‡ç´°èƒå› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬åŒ–å­¸å› å­æª¢æ¸¬å’ŒåŸºå› è¡¨é”åˆ†æã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—ç‚æœ‰é—œçš„é—œéµè·¯å¾‘ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBè·¯å¾‘ä¸‹ä¿ƒé€²æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™åœ¨ç‚ç—‡çš„è…¸é“ä¸Šçš®ä¸­è¡¨ç¾è¼ƒé«˜ï¼Œä¸¦è¢«å»ºè­°ä½œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ã€‚é€™äº›çµæœé©—è­‰äº†ä½¿ç”¨è…¸é“é¡å™¨å®˜ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªè—¥ç†æ¸¬è©¦å¹³å°çš„å¯è¡Œæ€§ï¼Œä¸¦é¡¯ç¤ºCAå’ŒSFNåœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ åƒé’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½è®“ä½ çš„è…¸é“æ›´å¥åº·ï¼é€™é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±æ¤°èœçš„è˜¿è””ç¡«ç´ å’Œè¿·è¿­é¦™ä¸­çš„è‚‰æ¡‚é…¸å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰å¹«åŠ©ï¼Œé€™æ˜¯ä¸€ç¨®æœƒè®“è…¸é“ç™¼ç‚çš„ç–¾ç—…ã€‚é€™é¡ç–¾ç—…ç›®å‰æ²’æœ‰æ ¹æ²»çš„æ–¹æ³•ï¼Œç¾æœ‰çš„æ²»ç™‚æœ‰æ™‚æœƒæœ‰å‰¯ä½œç”¨ï¼Œå› æ­¤æ‰¾åˆ°æ–°çš„ã€è‡ªç„¶çš„ç™‚æ³•æ˜¯ç›¸ç•¶é‡è¦çš„ï¼\n\nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é€™å…©ç¨®å¤©ç„¶æˆåˆ†ï¼Œæƒ³çŸ¥é“å®ƒå€‘èƒ½å¦æœ‰æ•ˆæ¸›å°‘ç‚ç—‡çš„æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²èº«é«”çš„æŠ—ç‚åæ‡‰ã€‚ä»–å€‘ä½¿ç”¨äº†è…¸é“ä¸Šçš®é¡å™¨å®˜ï¼Œé€™æ˜¯ä¸€ç¨®èƒ½æ¨¡æ“¬è…¸é“ç’°å¢ƒçš„ç´°èƒæ¨¡å‹ï¼Œä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„æ•ˆæœã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè‚‰æ¡‚é…¸å’Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç‚ç—‡æŒ‡æ¨™ï¼Œä¸¦æ¿€æ´»ä¸€æ¢èˆ‡æŠ—ç‚æœ‰é—œçš„è·¯å¾‘ã€‚\n\né€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œè‚‰æ¡‚é…¸å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“çš„ç‚ç—‡ã€‚\n2. é€™äº›å¤©ç„¶æˆåˆ†çš„ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°æ–¹å‘ã€‚\n3. ä½¿ç”¨è…¸é“é¡å™¨å®˜é€²è¡Œå¯¦é©—æ˜¯ä¸€ç¨®æœ‰æ•ˆçš„ç ”ç©¶æ–¹æ³•ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main findings of a study on the anti-inflammatory effects of sulforaphane from broccoli and cinnamic acid from rosemary. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨åˆ©ç”¨å¾®ç”Ÿç‰©è½‰åŒ–å¤©ç„¶æ´»æ€§ç‰©è³ªæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–æ¸›å°‘ç–¾ç—…é¢¨éšªã€‚é€™å°æ–¼æœªä¾†çš„ç‡Ÿé¤Šè£œå……å’Œå¥åº·ä¿ƒé€²ç­–ç•¥å¯èƒ½æœƒæœ‰é‡è¦çš„å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜å¾®ç”Ÿç‰© Lactiplantibacillus plantarum å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç‚ºä»€éº¼é€™ç¨®å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­çš„æ•ˆç‡ä¸é«˜ï¼Œä»¥åŠå¦‚ä½•é€éæŠ€è¡“æ‰‹æ®µä¾†æ”¹å–„é€™ä¸€é»ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å°æ–¼æœªä¾†çš„æ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æå‡ Lactiplantibacillus plantarum çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯é€™ç¨®å¾®ç”Ÿç‰©ï¼Œä¸¦é€éèª¿æ•´å…¶ç’°å¢ƒæ¢ä»¶ä¾†ä¿ƒé€²å…¶ä»£è¬éç¨‹ã€‚å…·é«”æ–¹æ³•åŒ…æ‹¬æ”¹è®Šè‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œä¸¦é€²è¡Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­çš„ä»£è¬è®ŠåŒ–ï¼Œé€™æ¨£å¯ä»¥æ›´æ¸…æ¥šåœ°äº†è§£å…¶å…§éƒ¨é‹ä½œæ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œå¾®ç”Ÿç‰©çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­æœƒèª¿æ•´å…¶ä»£è¬è·¯å¾‘ï¼Œä»¥æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚ç ”ç©¶çµæœæœ‰åŠ©æ–¼æ­ç¤º Lactiplantibacillus plantarum åœ¨è˜¿è””ç¡«ç´ è½‰åŒ–éç¨‹ä¸­çš„å…·é«”æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨åˆ©ç”¨å¾®ç”Ÿç‰©è½‰åŒ–å¤©ç„¶æ´»æ€§ç‰©è³ªæ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ã€‚é€éäº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–æ¸›å°‘ç–¾ç—…é¢¨éšªã€‚é€™å°æ–¼æœªä¾†çš„ç‡Ÿé¤Šè£œå……å’Œå¥åº·ä¿ƒé€²ç­–ç•¥å¯èƒ½æœƒæœ‰é‡è¦çš„å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜å¾®ç”Ÿç‰© Lactiplantibacillus plantarum å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œç‚ºä»€éº¼é€™ç¨®å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­çš„æ•ˆç‡ä¸é«˜ï¼Œä»¥åŠå¦‚ä½•é€éæŠ€è¡“æ‰‹æ®µä¾†æ”¹å–„é€™ä¸€é»ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºå¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å°æ–¼æœªä¾†çš„æ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æå‡ Lactiplantibacillus plantarum çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‡ã€‚ç ”ç©¶å°è±¡æ˜¯é€™ç¨®å¾®ç”Ÿç‰©ï¼Œä¸¦é€éèª¿æ•´å…¶ç’°å¢ƒæ¢ä»¶ä¾†ä¿ƒé€²å…¶ä»£è¬éç¨‹ã€‚å…·é«”æ–¹æ³•åŒ…æ‹¬æ”¹è®Šè‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œä¸¦é€²è¡Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­çš„ä»£è¬è®ŠåŒ–ï¼Œé€™æ¨£å¯ä»¥æ›´æ¸…æ¥šåœ°äº†è§£å…¶å…§éƒ¨é‹ä½œæ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œå¾®ç”Ÿç‰©çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜å¾®ç”Ÿç‰©åœ¨è½‰åŒ–éç¨‹ä¸­æœƒèª¿æ•´å…¶ä»£è¬è·¯å¾‘ï¼Œä»¥æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚ç ”ç©¶çµæœæœ‰åŠ©æ–¼æ­ç¤º Lactiplantibacillus plantarum åœ¨è˜¿è””ç¡«ç´ è½‰åŒ–éç¨‹ä¸­çš„å…·é«”æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“è£¡æœ‰ä¸€äº›å¾®ç”Ÿç‰©å¯ä»¥å¹«åŠ©æˆ‘å€‘è½‰åŒ–é£Ÿç‰©ä¸­çš„æœ‰ç›Šæˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼é€™ç¨®ç‰©è³ªå¯èƒ½å°å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼Œç”šè‡³èƒ½å¹«åŠ©é é˜²æŸäº›ç–¾ç—…ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨å¦‚ä½•æé«˜é€™äº›å¾®ç”Ÿç‰©çš„è½‰åŒ–æ•ˆç‡ã€‚\n\nç ”ç©¶è€…å€‘èšç„¦åœ¨ä¸€ç¨®å«åš Lactiplantibacillus plantarum çš„å¾®ç”Ÿç‰©ï¼Œæƒ³çŸ¥é“ç‚ºä»€éº¼å®ƒåœ¨è½‰åŒ–è˜¿è””ç¡«ç´ çš„éç¨‹ä¸­æ•ˆç‡ä¸é«˜ï¼Œä¸¦æƒ³å‡ºä¸€äº›æ–¹æ³•ä¾†æ”¹å–„ã€‚é€éèª¿æ•´ç’°å¢ƒæ¢ä»¶ï¼Œä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®å«åšé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œè®“é€™äº›å¾®ç”Ÿç‰©çš„ä»£è¬éç¨‹è®Šå¾—æ›´æœ‰æ•ˆç‡ã€‚\n\nå¯¦é©—çµæœé¡¯ç¤ºï¼Œç•¶ä»–å€‘æ”¹è®Šäº†å¾®ç”Ÿç‰©çš„ç‡Ÿé¤Šä¾†æºæ™‚ï¼Œé€™äº›å¾®ç”Ÿç‰©çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å»ä¸Šå‡ï¼Œé€™æ„å‘³è‘—å®ƒå€‘æ­£åœ¨èª¿æ•´è‡ªå·±çš„ä»£è¬è·¯å¾‘ä¾†å¢åŠ è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾ä¸åƒ…å¹«åŠ©æˆ‘å€‘äº†è§£å¾®ç”Ÿç‰©å¦‚ä½•èˆ‡å¤©ç„¶æˆåˆ†äº’å‹•ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œå°¤å…¶æ˜¯åœ¨ç–¾ç—…é é˜²æ–¹é¢ã€‚\n2. ç ”ç©¶æ¢ç´¢äº†å¾®ç”Ÿç‰© Lactiplantibacillus plantarum çš„è½‰åŒ–æ•ˆç‡ã€‚\n3. èª¿æ•´å¾®ç”Ÿç‰©çš„ç’°å¢ƒå¯ä»¥æå‡è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the conversion of sulforaphane by the microbe Lactiplantibacillus plantarum. Use a flat design style with a white or light-colored background and soft color palette. Include symbols for broccoli or sulforaphane, simplified representations of the experimental subjects (like humans or cells), arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' showing the metabolic changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼ç‚ç—‡æ€§ç–¾ç—…é¡¯ç¤ºå‡ºæ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘è‚è‡Ÿæå‚·æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å±éšœåŠŸèƒ½å’Œç‚ç—‡åæ‡‰ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²å’Œæ²»ç™‚ç›¸é—œçš„ç–¾ç—…ï¼Œåƒæ˜¯æ½°ç˜æ€§çµè…¸ç‚ç­‰ï¼Œé€²è€Œæå‡æ•´é«”å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ–¼èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§ç‚ç—‡æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“å’Œè‚è‡Ÿçš„æå‚·ï¼Œå› æ­¤é€™é …ç ”ç©¶å°æ–¼è©²ç–¾ç—…çš„ç†è§£å’Œæ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›è€é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸çš„æ”¹å–„ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2è¡¨é”çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦åˆ†æäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½ï¼Œä¸¦æŠ‘åˆ¶ç‚ç—‡åæ‡‰ã€‚è˜¿è””ç¡«ç´ é‚„æé«˜äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·äº†çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€äº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œä¿ƒé€²äº†M2å‹çš„è¡¨ç¾ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼ç‚ç—‡æ€§ç–¾ç—…é¡¯ç¤ºå‡ºæ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œæ¸›å°‘è‚è‡Ÿæå‚·æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å±éšœåŠŸèƒ½å’Œç‚ç—‡åæ‡‰ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²å’Œæ²»ç™‚ç›¸é—œçš„ç–¾ç—…ï¼Œåƒæ˜¯æ½°ç˜æ€§çµè…¸ç‚ç­‰ï¼Œé€²è€Œæå‡æ•´é«”å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°æ–¼èˆ‡æ½°ç˜æ€§çµè…¸ç‚ç›¸é—œçš„æ¬¡ç´šè‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦äº†è§£å…¶èƒŒå¾Œçš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®æ…¢æ€§ç‚ç—‡æ€§è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´è…¸é“å’Œè‚è‡Ÿçš„æå‚·ï¼Œå› æ­¤é€™é …ç ”ç©¶å°æ–¼è©²ç–¾ç—…çš„ç†è§£å’Œæ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚çš„æƒ…æ³ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°é€™äº›è€é¼ çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½åƒæ•¸çš„æ”¹å–„ï¼Œä»¥åŠè…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2è¡¨é”çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦åŠå…¶å—é«”çš„è¡¨é”ï¼Œä¸¦åˆ†æäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–æƒ…æ³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½ï¼Œä¸¦æŠ‘åˆ¶ç‚ç—‡åæ‡‰ã€‚è˜¿è””ç¡«ç´ é‚„æé«˜äº†çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·äº†çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€äº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œä¿ƒé€²äº†M2å‹çš„è¡¨ç¾ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚åŠå…¶ç›¸é—œçš„è‚æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœä¸åªæ˜¯ç‚ºäº†å¥åº·ï¼Œé‚„å¯èƒ½å°è…¸é“å’Œè‚è‡Ÿæœ‰ç¥å¥‡çš„æ•ˆæœï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå°æ–¼ç‚ç—‡æ€§ç–¾ç—…å¦‚æ½°ç˜æ€§çµè…¸ç‚æœ‰æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚ é€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•ä¿è­·è…¸é“å’Œè‚è‡Ÿï¼Œç‰¹åˆ¥æ˜¯å°æ–¼æ½°ç˜æ€§çµè…¸ç‚å¼•èµ·çš„è‚æå‚·ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨å°é¼ æ¨¡å‹æ¨¡æ“¬é€™ç¨®ç–¾ç—…ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›è¼•è…¸é“å’Œè‚è‡Ÿçš„æå‚·ï¼Œé‚„èƒ½æ”¹å–„è‚åŠŸèƒ½ï¼Œä¸¦æŠ‘åˆ¶ç‚ç—‡åæ‡‰ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼å¢å¼·è…¸é“å±éšœåŠŸèƒ½ï¼Œå¾è€Œå¯èƒ½æˆç‚ºè¼”åŠ©æ²»ç™‚çš„å¥½å¹«æ‰‹ã€‚ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå°è…¸é“å¥åº·æœ‰å¹«åŠ©ã€‚\n2. ç ”ç©¶ç™¼ç¾å®ƒèƒ½æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚çš„æå‚·ã€‚\n3. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ²»ç™‚ç›¸é—œç–¾ç—…çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental method and main results of the study on sulforaphane. Include simplified illustrations of broccoli and sulforaphane, along with simplified representations of mice. Use arrows or flow lines to depict the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and improvements observed, such as reduced inflammation and enhanced gut barrier function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ç‰¹åˆ¥å…·ä¾µç•¥æ€§çš„ç™Œç—‡äºå‹ï¼Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ï¼Œè€Œé€™é …ç ”ç©¶æ¢ç´¢äº†å¤©ç„¶ç”¢ç‰©çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œé¡¯ç¤ºå‡ºå°æŠ—è…«ç˜¤çš„å¸Œæœ›ã€‚é€™äº›æ–°å‹åŒ–åˆç‰©å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é‚£äº›å°å‚³çµ±ç™‚æ³•åæ‡‰ä¸ä½³çš„æ‚£è€…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢è¨å…¶å°ä¸‰é™°æ€§ä¹³ç™Œçš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯é€™äº›æ–°åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ¯”ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•æ›´æœ‰æ•ˆåœ°æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œæ“´æ•£ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æ›´å®‰å…¨ä¸”æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œç‰¹åˆ¥æ˜¯åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­ï¼Œè§€å¯Ÿå®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºå¹³å‡7.4å€çš„å¢å¼·æ•ˆæœï¼Œä¸¦ä¸”åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­å…·æœ‰è¼ƒä½çš„IC50å€¼ã€‚é€™å€‹åŒ–åˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æœ‰åŠ›å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ç‰¹åˆ¥å…·ä¾µç•¥æ€§çš„ç™Œç—‡äºå‹ï¼Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œé€šå¸¸ä¾è³´åŒ–ç™‚ï¼Œè€Œé€™é …ç ”ç©¶æ¢ç´¢äº†å¤©ç„¶ç”¢ç‰©çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œé¡¯ç¤ºå‡ºå°æŠ—è…«ç˜¤çš„å¸Œæœ›ã€‚é€™äº›æ–°å‹åŒ–åˆç‰©å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é‚£äº›å°å‚³çµ±ç™‚æ³•åæ‡‰ä¸ä½³çš„æ‚£è€…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢è¨å…¶å°ä¸‰é™°æ€§ä¹³ç™Œçš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯é€™äº›æ–°åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æ¯”ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•æ›´æœ‰æ•ˆåœ°æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œæ“´æ•£ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æ›´å®‰å…¨ä¸”æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œç‰¹åˆ¥æ˜¯åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­ï¼Œè§€å¯Ÿå®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§æ–¹é¢è¡¨ç¾å‡ºæœ€é«˜çš„æ•ˆèƒ½ï¼Œé¡¯ç¤ºå‡ºå¹³å‡7.4å€çš„å¢å¼·æ•ˆæœï¼Œä¸¦ä¸”åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­å…·æœ‰è¼ƒä½çš„IC50å€¼ã€‚é€™å€‹åŒ–åˆç‰©ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æœ‰åŠ›å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶å¯èƒ½è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼é€™ç¯‡ç ”ç©¶èšç„¦åœ¨ä¸€ç¨®ç‰¹åˆ¥çš„ä¹³ç™Œâ€”â€”ä¸‰é™°æ€§ä¹³ç™Œï¼Œé€™ç¨®ç™Œç—‡é€šå¸¸å¾ˆé›£æ²»ç™‚ï¼Œç ”ç©¶è€…å€‘æ­£åœ¨å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ–¹æ³•ä¾†å°æŠ—å®ƒã€‚é€™æ¬¡ï¼Œä»–å€‘æ¢ç´¢äº†å…©ç¨®å¤©ç„¶æˆåˆ†çš„çµ„åˆï¼šè˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡ï¼Œé€™äº›æ–°å‹åŒ–åˆç‰©åœ¨å¯¦é©—ä¸­å±•ç¾äº†å¸Œæœ›ï¼\n\nç ”ç©¶è€…å€‘åˆæˆäº†15ç¨®ä¸åŒçš„æ··åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾å…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©ï¼Œç¨±ç‚º17aï¼Œç«Ÿç„¶åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­ä¹Ÿèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„æ²»ç™‚é¸æ“‡å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. ç ”ç©¶é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼Œå°‹æ‰¾æ–°å‹æŠ—ç™Œæ²»ç™‚ã€‚  \n2. 17aåŒ–åˆç‰©åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå¼·å¤§çš„æŠ—ç™Œæ•ˆæœã€‚  \n3. é€™äº›çµæœå¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠç ”ç©¶é‹ªè·¯ï¼Œå€¼å¾—é—œæ³¨ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on a new anticancer compound. The image should have a white or light-colored background with soft colors. Include simple icons representing broccoli or compounds like sulforaphane, simplified representations of experimental subjects such as humans, animals, and cells. Use arrows or flow lines to indicate the experimental steps. Include a section clearly labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºæœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯ç•¶å®ƒå€‘èˆ‡å…¶ä»–ç‰©è³ªçµåˆæ™‚ï¼Œå¯èƒ½æœƒå‡ºç¾æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œæ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œç–¾ç—…é é˜²ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡å¸Œæœ›é€šéé€™é …ç ”ç©¶ï¼Œèƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£Nrf2é€™å€‹è½‰éŒ„å› å­åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚å…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºï¼ŒNrf2åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²è‚ºéƒ¨ç‚ç—‡ï¼Œè€Œé€™èˆ‡å®ƒé€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ï¼Œå› æ­¤æœ¬ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†48éš»C57BL/6Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œè¢«é€šéå’½å–‰å¸å…¥çš„æ–¹å¼æš´éœ²æ–¼ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§æ¥å—æ¯å¤©25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶åœ˜éšŠæ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œé€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæš´éœ²æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œç„¶è€Œåœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æƒ…æ³ä¸‹ï¼Œå»æ„å¤–åœ°ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€é€™äº›åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚ºéƒ¨ç‚ç—‡çš„æƒ…æ³ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ é€šå¸¸è¢«èªç‚ºæœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒæœ‰æ‰€ä¸åŒã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯ç•¶å®ƒå€‘èˆ‡å…¶ä»–ç‰©è³ªçµåˆæ™‚ï¼Œå¯èƒ½æœƒå‡ºç¾æ„æƒ³ä¸åˆ°çš„çµæœã€‚å› æ­¤ï¼Œæ·±å…¥äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„å¥åº·ç ”ç©¶å’Œç–¾ç—…é é˜²ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡å¸Œæœ›é€šéé€™é …ç ”ç©¶ï¼Œèƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£Nrf2é€™å€‹è½‰éŒ„å› å­åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚å…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºï¼ŒNrf2åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒä¿ƒé€²è‚ºéƒ¨ç‚ç—‡ï¼Œè€Œé€™èˆ‡å®ƒé€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ï¼Œå› æ­¤æœ¬ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†48éš»C57BL/6Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œè¢«é€šéå’½å–‰å¸å…¥çš„æ–¹å¼æš´éœ²æ–¼ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆ0ã€10æˆ–20å¾®å…‹ï¼‰ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§æ¥å—æ¯å¤©25æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§è™•ç†ã€‚ç ”ç©¶åœ˜éšŠæ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼Œé€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæš´éœ²æ–¼å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡æ¸›å°‘äº†å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œç„¶è€Œåœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æƒ…æ³ä¸‹ï¼Œå»æ„å¤–åœ°ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ä¸­å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€éNrf2çš„æ¿€æ´»ä¾†èª¿ç¯€é€™äº›åæ‡‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«ã€Œè˜¿è””ç¡«ç´ ã€çš„æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°è‚ºéƒ¨å¥åº·æœ‰è‘—æ„æƒ³ä¸åˆ°çš„å½±éŸ¿ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å°æ–¼ä¸€ç¨®å«å¤šå£ç¢³ç´ç±³ç®¡çš„ç‰©è³ªå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œè®“å®ƒå€‘å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œçµ¦äºˆè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ¥ä¸‹ä¾†ï¼Œä»–å€‘è§€å¯Ÿå°é¼ çš„è‚ºéƒ¨åæ‡‰ï¼ŒåŒ…æ‹¬è‚ºéƒ¨é‡é‡å’Œç´°èƒæ•¸é‡çš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¤§å¤šæ•¸æƒ…æ³ä¸‹èƒ½æ¸›å°‘è‚ºéƒ¨çš„ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨ä½åŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡æƒ…æ³ä¸‹ï¼Œå»æ„å¤–ä¿ƒé€²äº†æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ã€‚é€™è®“æˆ‘å€‘äº†è§£åˆ°è˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é›™é‡çš„ï¼Œä¸¦ä¸”å¯èƒ½æœƒå› ç‚ºä¸åŒçš„ç’°å¢ƒå› ç´ è€Œæœ‰æ‰€ä¸åŒã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å°è‚ºéƒ¨ç‚ç—‡æœ‰ä¿è­·ä½œç”¨ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹å¯èƒ½æœƒæœ‰æ„æƒ³ä¸åˆ°çš„æ•ˆæœã€‚\n2. ç ”ç©¶ä½¿ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿå…¶è‚ºéƒ¨åæ‡‰ã€‚\n3. äº†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æœªä¾†çš„å¥åº·ç ”ç©¶éå¸¸é‡è¦ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on a compound called 'sulforaphane' found in radishes. Include simplified illustrations of radishes, mice as experimental subjects, and arrows indicating the experimental steps. Highlight a section with key results, such as protective effects and changes in immune cell infiltration. Use soft colors and a clear, educational style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºéƒ¨ç‚ç—‡ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„åŒ–åˆç‰©ï¼Œå…·æœ‰å»£æ³›çš„æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½å°æ–¼é™ä½æŸäº›ç™Œç—‡é¢¨éšªæœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å‰åˆ—è…ºç™Œç­‰ç›¸é—œç–¾ç—…ã€‚äº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œèƒ½è®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨å®ƒå€‘ä¾†ä¿ƒé€²å¥åº·ï¼Œä¸¦å¯èƒ½åœ¨æœªä¾†çš„ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®é‡è¦ä½œç”¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠå®ƒåœ¨å¿ƒè‡Ÿç´°èƒæ¨¡å‹ä¸­å¯èƒ½ç”¢ç”Ÿçš„å‰¯ä½œç”¨ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„èƒ½è©•ä¼°å…¶å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰æ‰€çµ„æˆçš„å…±åŸ¹é¤Šæ¨¡å‹ã€‚é€™å€‹æ¨¡å‹å…è¨±åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å°PC-3å’ŒLNCaPç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿäº†å…¶å°å¿ƒè‚Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¿ƒè‡Ÿæ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒçš„æ­»äº¡ï¼Œè€Œä¸å½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œåœ¨PC-3ç´°èƒå…±åŸ¹é¤Šçš„æƒ…æ³ä¸‹ï¼Œå¿ƒè‚Œç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™èˆ‡å°ç…§çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„å·®ç•°ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—ç™Œæ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼ŒåŒæ™‚å°å¿ƒè‡Ÿçš„å½±éŸ¿ç›¸å°è¼ƒå°ï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡è—¥ç‰©ç ”ç©¶æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„åŒ–åˆç‰©ï¼Œå…·æœ‰å»£æ³›çš„æŠ—ç™Œç‰¹æ€§ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡æ¤ç‰©çš„æ”å–ï¼Œå¯èƒ½å°æ–¼é™ä½æŸäº›ç™Œç—‡é¢¨éšªæœ‰å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å‰åˆ—è…ºç™Œç­‰ç›¸é—œç–¾ç—…ã€‚äº†è§£é€™äº›å¤©ç„¶åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œèƒ½è®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨å®ƒå€‘ä¾†ä¿ƒé€²å¥åº·ï¼Œä¸¦å¯èƒ½åœ¨æœªä¾†çš„ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®é‡è¦ä½œç”¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠå®ƒåœ¨å¿ƒè‡Ÿç´°èƒæ¨¡å‹ä¸­å¯èƒ½ç”¢ç”Ÿçš„å‰¯ä½œç”¨ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„èƒ½è©•ä¼°å…¶å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒï¼ˆhiPSC-CMï¼‰æ‰€çµ„æˆçš„å…±åŸ¹é¤Šæ¨¡å‹ã€‚é€™å€‹æ¨¡å‹å…è¨±åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å°PC-3å’ŒLNCaPç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿäº†å…¶å°å¿ƒè‚Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¿ƒè‡Ÿæ”¶ç¸®åŠ›æ˜¯å¦å—åˆ°å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒçš„æ­»äº¡ï¼Œè€Œä¸å½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œåœ¨PC-3ç´°èƒå…±åŸ¹é¤Šçš„æƒ…æ³ä¸‹ï¼Œå¿ƒè‚Œç´°èƒçš„ç•°å¸¸è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™èˆ‡å°ç…§çµ„ç›¸æ¯”æœ‰æ˜é¡¯çš„å·®ç•°ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—ç™Œæ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼ŒåŒæ™‚å°å¿ƒè‡Ÿçš„å½±éŸ¿ç›¸å°è¼ƒå°ï¼Œé€™ç‚ºæœªä¾†çš„ç™Œç—‡è—¥ç‰©ç ”ç©¶æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½å°å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„åŒ–åˆç‰©ï¼Œå°å‰åˆ—è…ºç™Œç´°èƒæœ‰å¾ˆå¥½çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…©ç¨®ä¸åŒé¡å‹çš„å‰åˆ—è…ºç™Œç´°èƒï¼Œä¸¦ä¸”é‚„è€ƒæ…®äº†å®ƒå°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚ä»–å€‘åˆ©ç”¨ä¸€ç¨®ç‰¹åˆ¥çš„å¯¦é©—æ¨¡å‹ï¼Œè®“ç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒä¸€èµ·åŸ¹é¤Šï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°ä¸€ç¨®å‰åˆ—è…ºç™Œç´°èƒæ­»äº¡ï¼Œä¸¦ä¸”ä¸æœƒå½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ­£å¸¸æ”¶ç¸®åŠ›ï¼é€™æ„å‘³è‘—ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—ç™Œæ²»ç™‚ä¸­æœ‰æ½›åŠ›ï¼Œä¸¦ä¸”å°å¿ƒè‡Ÿçš„å½±éŸ¿ç›¸å°è¼ƒå°ã€‚ \n\né‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒæœ‰æ˜é¡¯çš„æŠ—ç™Œæ•ˆæœã€‚\n2. é€™ç¨®åŒ–åˆç‰©ä¸æœƒå½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„æ­£å¸¸åŠŸèƒ½ã€‚\n3. ç ”ç©¶ç‚ºæœªä¾†ç™Œç—‡è—¥ç‰©çš„é–‹ç™¼æä¾›äº†æ–°æ€è·¯ã€‚",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on sulforaphane. The image should have a simple and clear style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of human or cell subjects, arrows or flow lines to indicate experimental steps, and a section highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚ç­–ç•¥ã€‚ç ”ç©¶ä¸­ä½¿ç”¨çš„è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å·²çŸ¥å…·æœ‰å…ç–«èª¿ç¯€æ•ˆæœçš„åŒ–åˆç‰©ï¼Œä½†å…¶è‡¨åºŠæ‡‰ç”¨å—åˆ°ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦çš„é™åˆ¶ã€‚å› æ­¤ï¼Œå¦‚ä½•æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œå°æ–¼æœªä¾†çš„ç–¾ç—…æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼ˆå¦‚èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼‰ä¾†èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒåœ¨ç‚ç—‡ç‹€æ…‹ä¸‹è½‰è®Šç‚ºè€å—æ€§è¡¨å‹ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œé€™äº›æ”¹è‰¯çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©æ˜¯å¦èƒ½æœ‰æ•ˆèª¿ç¯€æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä¸¦é€²ä¸€æ­¥å½±éŸ¿Tç´°èƒçš„æ´»æ€§ï¼Œå¾è€Œé”åˆ°å…ç–«è€å—çš„æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ ç”˜éœ²ç³–è¡ç”Ÿç‰©ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ å‘‹å–ƒç³–è¡ç”Ÿç‰©ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿé€šè·¯çš„åƒèˆ‡æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè¡ç”Ÿç‰©å°æ¨¹çªç´°èƒçš„å½±éŸ¿åŠå…¶æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒè½‰è®Šç‚ºè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¼´éš¨SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä»¥åŠèª¿ç¯€æ€§Tç´°èƒçš„æ“´å±•å’Œç´°èƒæ¯’æ€§Tç´°èƒå¢æ®–çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§å¯¦é©—å’Œå…±ç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æœªèƒ½é”åˆ°é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚ç­–ç•¥ã€‚ç ”ç©¶ä¸­ä½¿ç”¨çš„è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å·²çŸ¥å…·æœ‰å…ç–«èª¿ç¯€æ•ˆæœçš„åŒ–åˆç‰©ï¼Œä½†å…¶è‡¨åºŠæ‡‰ç”¨å—åˆ°ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦çš„é™åˆ¶ã€‚å› æ­¤ï¼Œå¦‚ä½•æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œå°æ–¼æœªä¾†çš„ç–¾ç—…æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼ˆå¦‚èˆ‡ç”˜éœ²ç³–æˆ–å‘‹å–ƒç³–çµåˆçš„å½¢å¼ï¼‰ä¾†èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒåœ¨ç‚ç—‡ç‹€æ…‹ä¸‹è½‰è®Šç‚ºè€å—æ€§è¡¨å‹ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œé€™äº›æ”¹è‰¯çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©æ˜¯å¦èƒ½æœ‰æ•ˆèª¿ç¯€æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä¸¦é€²ä¸€æ­¥å½±éŸ¿Tç´°èƒçš„æ´»æ€§ï¼Œå¾è€Œé”åˆ°å…ç–«è€å—çš„æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€è˜¿è””ç¡«ç´ ç”˜éœ²ç³–è¡ç”Ÿç‰©ï¼ˆSFNManï¼‰å’Œè˜¿è””ç¡«ç´ å‘‹å–ƒç³–è¡ç”Ÿç‰©ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›ç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿé€šè·¯çš„åƒèˆ‡æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè¡ç”Ÿç‰©å°æ¨¹çªç´°èƒçš„å½±éŸ¿åŠå…¶æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒè½‰è®Šç‚ºè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¼´éš¨SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä»¥åŠèª¿ç¯€æ€§Tç´°èƒçš„æ“´å±•å’Œç´°èƒæ¯’æ€§Tç´°èƒå¢æ®–çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§å¯¦é©—å’Œå…±ç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€ŒSFNFucå‰‡æœªèƒ½é”åˆ°é€™ä¸€æ•ˆæœã€‚é€™äº›çµæœç¢ºèªäº†NFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é—œéµè§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©è£¡çš„æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å…ç–«ç³»çµ±æœ‰å¾ˆå¤§çš„å½±éŸ¿ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªè˜¿è””å’Œé’èŠ±æ¤°èœï¼‰å¦‚ä½•å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±ä¿æŒå¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„æ™‚å€™ã€‚ç ”ç©¶åœ˜éšŠç™¼ç¾ï¼Œé€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ–°çš„æ²»ç™‚æ–¹æ¡ˆï¼\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘å°‡äººé¡çš„å…ç–«ç´°èƒæ”¾åœ¨æ¨¡æ“¬ç‚ç—‡çš„ç’°å¢ƒä¸­ï¼Œç„¶å¾Œåˆ†åˆ¥ç”¨ä¸åŒçš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©é€²è¡Œè™•ç†ï¼Œè§€å¯Ÿå®ƒå€‘å°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼ŒæŸç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©èƒ½æœ‰æ•ˆåœ°å¹«åŠ©æ¨¹çªç´°èƒè½‰è®Šç‚ºã€Œè€å—æ€§ã€çš„ç‹€æ…‹ï¼Œé€™æ„å‘³è‘—å®ƒå€‘èƒ½æ›´å¥½åœ°èª¿ç¯€å…ç–«åæ‡‰ï¼Œæ¸›å°‘éåº¦çš„ç‚ç—‡ã€‚\n\nğŸ”ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©å…ç–«ç³»çµ±ä¿æŒå¹³è¡¡ï¼Œæ¸›å°‘ç‚ç—‡ã€‚\n2. ç‰¹å®šè¡ç”Ÿç‰©èƒ½ä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œå½±éŸ¿Tç´°èƒæ´»æ€§ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†é‡å°è‡ªé«”å…ç–«ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create an infographic illustrating the experiment and main findings of a study on sulforaphane. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and changes in immune cell behavior.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œéå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå±åŠç”Ÿå‘½ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰åœ¨é€™ç¨®ç–¾ç—…çš„ç™¼å±•ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œå› æ­¤å°‹æ‰¾é‡å°é€™äº›æ©Ÿåˆ¶çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„é‡å°æ€§æ²»ç™‚æ–¹æ³•ä»ç„¶ç¼ºä¹ï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœï¼Œå°æ–¼æ”¹å–„TTSæ‚£è€…çš„é å¾Œå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚é€™äº›æ¨¡å‹ç”¨ä¾†æ¨¡æ“¬TTSçš„ç—…ç†ç‹€æ…‹ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç›Šè™•æœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„çµæœæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œéå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå±åŠç”Ÿå‘½ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰åœ¨é€™ç¨®ç–¾ç—…çš„ç™¼å±•ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œå› æ­¤å°‹æ‰¾é‡å°é€™äº›æ©Ÿåˆ¶çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„é‡å°æ€§æ²»ç™‚æ–¹æ³•ä»ç„¶ç¼ºä¹ï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœï¼Œå°æ–¼æ”¹å–„TTSæ‚£è€…çš„é å¾Œå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚é€™äº›æ¨¡å‹ç”¨ä¾†æ¨¡æ“¬TTSçš„ç—…ç†ç‹€æ…‹ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç›Šè™•æœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œèƒ½åŒæ™‚é‡å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œç‚ºæ”¹å–„TTSçš„çµæœæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿä¹Ÿæœƒå—åˆ°å£“åŠ›å½±éŸ¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ä¸€ç¨®å«åšTakotsuboç—‡å€™ç¾¤ï¼ˆç°¡ç¨±TTSï¼‰çš„ç–¾ç—…ä¸Šã€‚é€™ç¨®ç—‡å€™ç¾¤æœƒè®“å¿ƒè‡Ÿå—åˆ°æå‚·ï¼Œéå»æˆ‘å€‘ä»¥ç‚ºå®ƒä¸æœƒå¤ªåš´é‡ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒå±åŠç”Ÿå‘½ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªèƒ½å¦å¹«åŠ©æ¸›è¼•å› æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡é€ æˆçš„å¿ƒè‡Ÿæå‚·ã€‚ä»–å€‘ç”¨è€é¼ å’Œå¿ƒè‡Ÿç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„å¢å¼·äº†æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘äº†ç´°èƒæå‚·çš„æ¨™è¨˜ç‰©ã€‚é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå°æŠ—TTSçš„ä¸€ç¨®æ–°æ–¹æ³•ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½ã€‚\n2. å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚\n3. Nrf2ï¼ˆå…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼‰åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main findings of a study on the effects of sulforaphane on Takotsubo syndrome. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or heart cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as protective effects and observed changes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ åœ¨æŸç¨®ç¨‹åº¦ä¸Šä¿è­·è‚ºéƒ¨å¥åº·ï¼Œé™ä½å¸ç…™å°èº«é«”çš„è² é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€SIRT1çš„è¡¨é”ä¾†æ¸›è¼•é€™äº›æå®³ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œå‰‡ä½¿ç”¨è…¹è…”æ³¨å°„çš„æ–¹å¼å¼•ç™¼è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿåœ¨28å¤©å…§çš„çµ„ç¹”è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶ç”±å¸ç…™å¼•èµ·çš„éµæ­»äº¡ç¾è±¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·æ•ˆæœï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„è‡¨åºŠæ‡‰ç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå®³ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œæˆ–è¨±èƒ½å¤ åœ¨æŸç¨®ç¨‹åº¦ä¸Šä¿è­·è‚ºéƒ¨å¥åº·ï¼Œé™ä½å¸ç…™å°èº«é«”çš„è² é¢å½±éŸ¿ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€SIRT1çš„è¡¨é”ä¾†æ¸›è¼•é€™äº›æå®³ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ä¾æ“šã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œå‰‡ä½¿ç”¨è…¹è…”æ³¨å°„çš„æ–¹å¼å¼•ç™¼è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿåœ¨28å¤©å…§çš„çµ„ç¹”è®ŠåŒ–ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„æ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦æŠ‘åˆ¶ç”±å¸ç…™å¼•èµ·çš„éµæ­»äº¡ç¾è±¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·æ•ˆæœï¼Œé›–ç„¶ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„è‡¨åºŠæ‡‰ç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ï¼Œè®“å¾ˆå¤šäººéƒ½æ„Ÿåˆ°æ“”æ†‚ï¼Œä½†æœ‰ä¸€ç¨®é£Ÿææˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±èœå’Œè˜¿è””ç­‰è”¬èœï¼‰å¯èƒ½å°æŠ—å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·æœ‰æ½›åœ¨çš„ä¿è­·æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯å¸ç…™ç…™éœ§å°æˆ‘å€‘è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›è¼•é€™äº›æå®³ã€‚  \n\nç ”ç©¶è€…ä½¿ç”¨äº†äººé¡çš„æ°£é“ç´°èƒå’Œå°é¼ é€²è¡Œå¯¦é©—ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶é€™äº›ç´°èƒæ¥è§¸åˆ°å¸ç…™ç…™éœ§å¾Œï¼Œè˜¿è””ç¡«ç´ çš„åŠ å…¥èƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒçš„æ­»äº¡å’Œè€åŒ–ç¾è±¡ï¼Œä¸¦æ”¹å–„å°é¼ çš„è‚ºéƒ¨å¥åº·ã€‚  \n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œæˆ–è¨±é€éå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–ï¼Œèƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šä¿è­·è‚ºéƒ¨ï¼Œå°¤å…¶å°æ–¼å¸ç…™è€…å’Œé•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œé€™æ˜¯å€‹å¥½æ¶ˆæ¯ï¼  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚  \n2. ç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹å–„ç´°èƒå­˜æ´»ç‡å’Œæ¸›å°‘è€åŒ–ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†å¯èƒ½çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°æ–¹å‘ã€‚",
    "image_prompt": "Create an infographic illustrating the experimental process and main findings of a study on the protective effects of sulforaphane against smoking-induced lung damage. Include simplified icons of broccoli and radish to represent sulforaphane, human airway cells, and mice as experimental subjects. Use arrows or flow lines to show the steps of the experiment. Add a section that highlights the main results, such as the protective effects and improvements observed in lung health.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå®ƒåœ¨æŠ—ç™¼ç‚æ–¹é¢çš„ç‰¹æ€§ä½¿å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­å—åˆ°å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦ä¹Ÿèƒ½å¹«åŠ©æ¸›ç·©çš®è†šçš„å…§åœ¨è€åŒ–ï¼Œé€™å°æ–¼æ”¹å–„çš®è†šå¥åº·å’Œé é˜²è€åŒ–ç›¸é—œçš„å•é¡Œå¯èƒ½æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„çš®è†šçµæ§‹ã€èª¿ç¯€ç´…æ°§å¹³è¡¡ä»¥åŠå½±éŸ¿å…ç–«ç´°èƒçš„çµ„æˆï¼Œå¾è€Œæ¸›ç·©çš®è†šè€åŒ–çš„éç¨‹ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„çš®è†šè€åŒ–æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚å°é¼ åœ¨å…©å€‹æœˆå…§æ¥å—äº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°çš®è†šçµæ§‹çš„é¡¯è‘—æ”¹å–„ã€ç´…æ°§å¹³è¡¡çš„ç©©å®šä»¥åŠå…ç–«ç´°èƒçš„çµ„æˆè®ŠåŒ–ã€‚æ­¤å¤–ï¼Œé€éè›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œç ”ç©¶åœ˜éšŠç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰èˆ‡å…§åœ¨çš®è†šè€åŒ–ç›¸é—œçš„è›‹ç™½è³ªè¡¨ç¾ï¼Œé€™äº›ç™¼ç¾ç‚ºç†è§£å…¶ä½œç”¨æ©Ÿåˆ¶æä¾›äº†é‡è¦æ•¸æ“šã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”é€éæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ è£œå……çš„å°é¼ ä¸­è¡¨ç¾å‡ºé¡¯è‘—è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡å…ç–«ç´°èƒçš„æ»²é€å’Œæ•´é«”è¡€æ¶²ç´°èƒåˆ†æç›¸é—œçš„çµæœï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ æŒ½æ•‘çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„æ¸›å°‘ï¼Œé€™äº›çµæœç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„æ½›åœ¨ç›®æ¨™ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±æ„Ÿã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå®ƒåœ¨æŠ—ç™¼ç‚æ–¹é¢çš„ç‰¹æ€§ä½¿å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­å—åˆ°å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦ä¹Ÿèƒ½å¹«åŠ©æ¸›ç·©çš®è†šçš„å…§åœ¨è€åŒ–ï¼Œé€™å°æ–¼æ”¹å–„çš®è†šå¥åº·å’Œé é˜²è€åŒ–ç›¸é—œçš„å•é¡Œå¯èƒ½æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶äººå“¡é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„çš®è†šçµæ§‹ã€èª¿ç¯€ç´…æ°§å¹³è¡¡ä»¥åŠå½±éŸ¿å…ç–«ç´°èƒçš„çµ„æˆï¼Œå¾è€Œæ¸›ç·©çš®è†šè€åŒ–çš„éç¨‹ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„çš®è†šè€åŒ–æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚å°é¼ åœ¨å…©å€‹æœˆå…§æ¥å—äº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°çš®è†šçµæ§‹çš„é¡¯è‘—æ”¹å–„ã€ç´…æ°§å¹³è¡¡çš„ç©©å®šä»¥åŠå…ç–«ç´°èƒçš„çµ„æˆè®ŠåŒ–ã€‚æ­¤å¤–ï¼Œé€éè›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œç ”ç©¶åœ˜éšŠç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¤ é€†è½‰èˆ‡å…§åœ¨çš®è†šè€åŒ–ç›¸é—œçš„è›‹ç™½è³ªè¡¨ç¾ï¼Œé€™äº›ç™¼ç¾ç‚ºç†è§£å…¶ä½œç”¨æ©Ÿåˆ¶æä¾›äº†é‡è¦æ•¸æ“šã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”é€éæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œé€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ è£œå……çš„å°é¼ ä¸­è¡¨ç¾å‡ºé¡¯è‘—è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œèˆ‡å…ç–«ç´°èƒçš„æ»²é€å’Œæ•´é«”è¡€æ¶²ç´°èƒåˆ†æç›¸é—œçš„çµæœï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ æŒ½æ•‘çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„æ¸›å°‘ï¼Œé€™äº›çµæœç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„æ½›åœ¨ç›®æ¨™ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒè®Šå¾—è¶Šä¾†è¶Šè„†å¼±ï¼Œé€™å¯èƒ½æœƒè®“æˆ‘å€‘æ„Ÿåˆ°ä¸å®‰ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªåœ¨æŠ—ç™¼ç‚æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œç”šè‡³åœ¨ç™Œç—‡æ²»ç™‚ä¸­ä¹Ÿæœ‰æ‡‰ç”¨ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©æ¸›ç·©çš®è†šçš„å…§åœ¨è€åŒ–ï¼Œé€™å°æˆ‘å€‘çš„çš®è†šå¥åº·å’ŒæŠ—è€åŒ–æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼\n\né€™é …ç ”ç©¶ä½¿ç”¨äº†18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ ä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„æƒ…æ³ã€‚å°é¼ åœ¨å…©å€‹æœˆå…§æ¥å—äº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œçµæœé¡¯ç¤ºå‡ºçš®è†šçµæ§‹æœ‰æ˜é¡¯æ”¹å–„ï¼Œç´…æ°§å¹³è¡¡ä¹Ÿè®Šå¾—ç©©å®šï¼Œå…ç–«ç´°èƒçš„çµ„æˆä¹Ÿæœ‰äº†è®ŠåŒ–ã€‚é€éåˆ†æï¼Œç ”ç©¶åœ˜éšŠç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€†è½‰èˆ‡çš®è†šè€åŒ–ç›¸é—œçš„è›‹ç™½è³ªè¡¨ç¾ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„æŠ—è€åŒ–æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ã€‚\n2. é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ï¼Œè˜¿è””ç¡«ç´ å¹«åŠ©ç¶­æŒçš®è†šå¥åº·ã€‚\n3. ç ”ç©¶çµæœæ­ç¤ºäº†å°æŠ—çš®è†šè€åŒ–çš„æ–°æ½›åœ¨ç›®æ¨™ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of the study on sulforaphane. The image should have a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified graphics of experimental subjects like mice or cells, arrows or flow lines indicating the steps of the experiment, and a section clearly labeling the 'Main Results' such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾å¤©ç„¶ç‰©è³ªä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·å½±éŸ¿çš„ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘äº†è§£å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“ç‰©çš„æƒ…æ³ä¸‹ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼ç†è§£ç’°å¢ƒæ¯’ç´ å°ç”Ÿç‰©é«”çš„å½±éŸ¿åŠå…¶æ½›åœ¨çš„ä¿è­·æªæ–½éå¸¸é‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸ8é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡ŸæŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œä¸¦æ¢å¾©ä¸€äº›åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚é€™äº›çµæœç‚ºé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘æ¯’æ€§å½±éŸ¿æ–¹é¢çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾å¤©ç„¶ç‰©è³ªä¾†æ¸›å°‘ç’°å¢ƒæ¯’ç´ å°å¥åº·å½±éŸ¿çš„ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½å¹«åŠ©æˆ‘å€‘äº†è§£å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“ç‰©çš„æƒ…æ³ä¸‹ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å¦‚ä½•å½±éŸ¿é­šé¡çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›ä¸è‰¯å½±éŸ¿ã€‚é€™å°æ–¼ç†è§£ç’°å¢ƒæ¯’ç´ å°ç”Ÿç‰©é«”çš„å½±éŸ¿åŠå…¶æ½›åœ¨çš„ä¿è­·æªæ–½éå¸¸é‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸ8é€±çš„å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«çš„çµ„åˆ¥ï¼Œä»¥åŠåŒæ™‚æ¥å—10å¾®å…‹/å‡ä¸‰è‹¯éŒ«å’Œ10æ¯«å…‹/å…¬æ–¤è˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€‚ç ”ç©¶è€…é€šéè§€å¯Ÿé€™äº›é­šçš„è‚è‡ŸæŒ‡æ¨™ã€å…ç–«åŸºå› è¡¨é”å’Œè…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è‚è‡Ÿä¸­çš„è†½é…¸ç©ç´¯ï¼Œä¸¦æ¢å¾©ä¸€äº›åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶æ–¹é¢çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚é€™äº›çµæœç‚ºé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘æ¯’æ€§å½±éŸ¿æ–¹é¢çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©è£¡é¢è—è‘—å¼·å¤§çš„å¥åº·ç§˜å¯†ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰ä¿è­·ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç’°å¢ƒæ±¡æŸ“ç‰©çš„æŒ‘æˆ°æ™‚ã€‚é€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸ8é€±çš„å¯¦é©—ï¼Œè§€å¯Ÿå®ƒå€‘çš„è‚è‡Ÿå¥åº·å’Œå…ç–«è¡¨ç¾ã€‚çµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²æœƒé€ æˆè‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œä½†ç•¶é­šé¡æ”å–äº†è˜¿è””ç¡«ç´ å¾Œï¼Œè‚è‡Ÿçš„è†½é…¸ç©ç´¯æ¸›å°‘ï¼Œå…ç–«ç³»çµ±çš„è¡¨ç¾ä¹Ÿæœ‰æ‰€æ”¹å–„ï¼Œè…¸é“å¥åº·ä¹Ÿå¾—åˆ°äº†æå‡ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†å¤©ç„¶æˆåˆ†åœ¨å°æŠ—ç’°å¢ƒæ¯’ç´ æ–¹é¢çš„æ½›åŠ›ã€‚  \n\nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ¯’æ€§å½±éŸ¿ã€‚  \n2. å¯èƒ½æå‡å…ç–«ç³»çµ±åŠŸèƒ½ï¼Œå°æŠ—ç’°å¢ƒæ±¡æŸ“ã€‚  \n3. æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„æˆï¼Œæœ‰åŠ©æ–¼æ•´é«”å¥åº·ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on the protective effects of sulforaphane. Include simplified representations of broccoli or sulforaphane, experimental subjects like fish or cells, and arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting key findings such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚æ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®ç–¾ç—…ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å±éšœåŠŸèƒ½å¤±èª¿æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œé€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå…¶ä»£è¬ç‰©ï¼Œä¾†æ¸›å°‘è…¸é“çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é–‹ç™¼é‡å°æ½°ç˜æ€§çµè…¸ç‚çš„è—¥ç‰©æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥æ¢è¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æ‰€å¼•èµ·çš„ç‚ç—‡ã€‚é€™å€‹å•é¡Œéå¸¸é‡è¦ï¼Œå› ç‚ºè…¸é“å¾®ç”Ÿç‰©çš„å¥åº·ç‹€æ…‹èˆ‡å¤šç¨®è…¸é“ç–¾ç—…çš„ç™¼å±•å¯†åˆ‡ç›¸é—œï¼Œå°¤å…¶æ˜¯æ½°ç˜æ€§çµè…¸ç‚é€™é¡ç–¾ç—…ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚é€™äº›å°é¼ è¢«çµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…è§€å¯Ÿå…¶å°ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©çµ„çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°å¾®ç”Ÿç‰©çµ„æˆçš„èª¿æ•´æ•ˆæœï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æ–¹æ³•ä¾†åˆ†æè…¸é“å…§çš„ä»£è¬è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©çµ„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–å¾—åˆ°äº†é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚å¾Œï¼ŒMAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯åœ¨å°é¼ çµè…¸ä¸­çš„æ´»æ€§å—åˆ°æŠ‘åˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ¸›è¼•çµè…¸ç‚çš„ç—‡ç‹€ï¼Œä¸¦æ”¹å–„è…¸é“åŠŸèƒ½ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰é€™ç¨®ç–¾ç—…ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å±éšœåŠŸèƒ½å¤±èª¿æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œé€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå…¶ä»£è¬ç‰©ï¼Œä¾†æ¸›å°‘è…¸é“çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é–‹ç™¼é‡å°æ½°ç˜æ€§çµè…¸ç‚çš„è—¥ç‰©æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„æ½›åŠ›å€¼å¾—é€²ä¸€æ­¥æ¢è¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çµ„å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±èª¿æ‰€å¼•èµ·çš„ç‚ç—‡ã€‚é€™å€‹å•é¡Œéå¸¸é‡è¦ï¼Œå› ç‚ºè…¸é“å¾®ç”Ÿç‰©çš„å¥åº·ç‹€æ…‹èˆ‡å¤šç¨®è…¸é“ç–¾ç—…çš„ç™¼å±•å¯†åˆ‡ç›¸é—œï¼Œå°¤å…¶æ˜¯æ½°ç˜æ€§çµè…¸ç‚é€™é¡ç–¾ç—…ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚é€™äº›å°é¼ è¢«çµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…è§€å¯Ÿå…¶å°ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸çš„ç‚ç—‡ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©çµ„çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°å¾®ç”Ÿç‰©çµ„æˆçš„èª¿æ•´æ•ˆæœï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æ–¹æ³•ä¾†åˆ†æè…¸é“å…§çš„ä»£è¬è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©çµ„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–å¾—åˆ°äº†é¡¯è‘—æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚å¾Œï¼ŒMAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯åœ¨å°é¼ çµè…¸ä¸­çš„æ´»æ€§å—åˆ°æŠ‘åˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ¸›è¼•çµè…¸ç‚çš„ç—‡ç‹€ï¼Œä¸¦æ”¹å–„è…¸é“åŠŸèƒ½ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””è£¡é¢æœ‰ä»€éº¼ç§˜å¯†å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯å°æ½°ç˜æ€§çµè…¸ç‚é€™ç¨®æ…¢æ€§ç–¾ç—…ï¼é€™ç¨®ç–¾ç—…æœƒå½±éŸ¿æˆ‘å€‘çš„è…¸é“ï¼Œè®“è…¸é“çš„å±éšœåŠŸèƒ½è®Šå·®ï¼Œå¯èƒ½å°è‡´ç‚ç—‡ã€‚  \n  \nç ”ç©¶äººå“¡æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çµ„ï¼Œé€™äº›å¾®ç”Ÿç‰©å°æˆ‘å€‘çš„å¥åº·éå¸¸é‡è¦ã€‚ä»–å€‘ç”¨ä¸€ç¨®ç‰¹æ®Šçš„æ–¹æ³•ï¼Œè®“å°é¼ çš„è…¸é“å‡ºç¾å•é¡Œï¼Œç„¶å¾Œçµ¦å®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿé€™ç¨®ç‰©è³ªçš„æ•ˆæœã€‚  \n  \nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å°é¼ çš„è…¸é“å¥åº·ï¼Œé‚„æ¸›å°‘äº†è…¸é“çš„ç‚ç—‡ï¼Œç”šè‡³å¹«åŠ©é‡æ–°å¹³è¡¡äº†è…¸é“è£¡çš„å¾®ç”Ÿç‰©ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ åœ¨æœªä¾†æ²»ç™‚æ½°ç˜æ€§çµè…¸ç‚æ–¹é¢çš„æ½›åŠ›ã€‚  \n  \nâœ¨ ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚  \n2. å®ƒå¯ä»¥æ¸›å°‘è…¸é“çš„ç‚ç—‡åæ‡‰ã€‚  \n3. ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çµ„ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the effects of sulforaphane from radishes on gut health. Include symbols representing broccoli or radish, simplified illustrations of experimental subjects like mice, and arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šç¨®ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨æ”¹å–„è‚è‡Ÿå¥åº·æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºæ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿæˆ–è£œå……è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°æŠ—æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›é¢è‡¨ç™Œç—‡é¢¨éšªçš„äººä¾†èªªï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°æ–¼Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œå¿ƒè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥åŠå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚é€éä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†åŒ…è£¹è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æå‡å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²ä¸€æ­¥äº†è§£å…¶åœ¨æŠ—ç™Œéç¨‹ä¸­çš„å…·é«”è¡¨ç¾ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬ä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ã€ä»¥åŠå¸¶æœ‰EACçš„è€é¼ ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€è‚è‡Ÿå¥åº·ç­‰å¤šé …æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­é€šè·¯ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©å’Œæ´»ç´°èƒæ•¸é‡æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šç¨®ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨æ”¹å–„è‚è‡Ÿå¥åº·æ–¹é¢ä¹Ÿé¡¯ç¤ºå‡ºæ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿæˆ–è£œå……è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°æŠ—æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²æ•´é«”å¥åº·ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›é¢è‡¨ç™Œç—‡é¢¨éšªçš„äººä¾†èªªï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°æ–¼Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œå¿ƒè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥åŠå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚é€éä½¿ç”¨ç´ç±³è„‚è³ªé«”ä¾†åŒ…è£¹è˜¿è””ç¡«ç´ ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æå‡å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œé€²ä¸€æ­¥äº†è§£å…¶åœ¨æŠ—ç™Œéç¨‹ä¸­çš„å…·é«”è¡¨ç¾ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬ä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ã€ä»¥åŠå¸¶æœ‰EACçš„è€é¼ ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€è‚è‡Ÿå¥åº·ç­‰å¤šé …æŒ‡æ¨™ï¼Œä¸¦åˆ†æäº†ç›¸é—œçš„åˆ†å­é€šè·¯ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©å’Œæ´»ç´°èƒæ•¸é‡æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å„ä½æœ‹å‹ï¼Œä½ å€‘çŸ¥é“è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°å¥åº·æœ‰å¤šå¤§çš„æ½›åŠ›å—ï¼Ÿæœ€è¿‘ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸Šæœ‰è‘—æ„æƒ³ä¸åˆ°çš„æ•ˆæœï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ èº«ä¸Šå°æŠ—ä¸€ç¨®å«åšEhrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„è…«ç˜¤çš„æ•ˆæœã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®æ–°æŠ€è¡“ï¼Œå°‡è˜¿è””ç¡«ç´ åŒ…è£¹åœ¨ç´ç±³è„‚è³ªé«”ä¸­ï¼Œé€™æ¨£å¯ä»¥æé«˜å®ƒçš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œè®“æˆ‘å€‘æ›´æ¸…æ¥šå®ƒåœ¨æŠ—ç™Œéç¨‹ä¸­çš„è¡¨ç¾ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œ90éš»å°é¼ è¢«åˆ†æˆå¹¾çµ„ï¼Œæ¥å—ä¸åŒçš„è™•ç†ï¼ŒæŒçºŒ20å¤©ã€‚ç ”ç©¶è€…è§€å¯Ÿè…«ç˜¤çš„å¤§å°ã€å­˜æ´»ç‡å’Œè‚è‡Ÿå¥åº·ç­‰æŒ‡æ¨™ï¼Œä¸¦åˆ†æç›¸é—œçš„ç”Ÿç‰©é€šè·¯ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä½¿ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæ´»ç´°èƒæ•¸é‡ä¸Šï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´å¥½ï¼Œé‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚\n2. ç´ç±³è„‚è³ªé«”èƒ½æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚\n3. ç ”ç©¶é¡¯ç¤ºæ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "image_prompt": "Create a simple and informative illustration explaining the experimental method and main results of a study on sulforaphane (SFN). Use a flat design style with a white or light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified depictions of experimental subjects (like mice or cells), arrows or flow lines indicating the experimental steps, and a section highlighting the 'Main Results' such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œè½‰ç§»ï¼Œä¸¦æ‰¾å‡ºç›¸é—œçš„åˆ†å­æ¨™é¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘åœ¨é«”å¤–å’Œé«”å…§é€²è¡Œäº†å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚ç ”ç©¶ç™¼ç¾ï¼ŒCKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CKMT2-AS1èƒ½èˆ‡RNAçµåˆè›‹ç™½AIMP1ç›´æ¥çµåˆï¼Œä¿ƒé€²AIMP1çš„é™è§£ï¼Œé€²ä¸€æ­¥å½±éŸ¿PI3K/AKTä¿¡è™Ÿé€šè·¯çš„æ´»æ€§ï¼Œé€™åœ¨å¤§å¤šæ•¸å¯¦é«”è…«ç˜¤ä¸­éƒ½æ˜¯éåº¦æ´»åŒ–çš„ã€‚",
    "explanation_zh": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œè½‰ç§»ï¼Œä¸¦æ‰¾å‡ºç›¸é—œçš„åˆ†å­æ¨™é¶ï¼Œä»¥ä¾¿æœªä¾†èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘åœ¨é«”å¤–å’Œé«”å…§é€²è¡Œäº†å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚ç ”ç©¶ç™¼ç¾ï¼ŒCKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CKMT2-AS1èƒ½èˆ‡RNAçµåˆè›‹ç™½AIMP1ç›´æ¥çµåˆï¼Œä¿ƒé€²AIMP1çš„é™è§£ï¼Œé€²ä¸€æ­¥å½±éŸ¿PI3K/AKTä¿¡è™Ÿé€šè·¯çš„æ´»æ€§ï¼Œé€™åœ¨å¤§å¤šæ•¸å¯¦é«”è…«ç˜¤ä¸­éƒ½æ˜¯éåº¦æ´»åŒ–çš„ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶å¯èƒ½éš±è—è‘—å°æŠ—èƒƒç™Œçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±æ¤°èœå’Œå…¶ä»–åå­—èŠ±ç§‘è”¬èœï¼‰åœ¨å°æŠ—èƒƒç™Œæ–¹é¢å¯èƒ½æœ‰é©šäººçš„æ½›åŠ›ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œè½‰ç§»ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼ŒåŒ…æ‹¬åŸºå› åˆ†æï¼Œä¾†æ‰¾å‡ºè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶ç™Œç´°èƒçš„å¢é•·ï¼Œé‚„èƒ½å½±éŸ¿ä¸€äº›ç›¸é—œçš„åˆ†å­ï¼Œé€™å°æœªä¾†çš„æ²»ç™‚æ–¹æ³•å¯èƒ½æœƒæœ‰å¾ˆå¤§å¹«åŠ©ã€‚\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶æŒ‡å‡ºç•¶æŸç¨®åç‚ºCKMT2-AS1çš„åˆ†å­è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»éƒ½æœ‰é¡¯è‘—æ¸›å°‘ï¼Œé€™å¯èƒ½æ„å‘³è‘—æˆ‘å€‘æ‰¾åˆ°äº†ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é—œéµé»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ã€‚  \n2. CKMT2-AS1èˆ‡èƒƒç™Œçš„æƒ¡æ€§ç‰¹å¾µæœ‰é—œã€‚  \n3. ç ”ç©¶çµæœç‚ºæœªä¾†é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥æä¾›äº†å¸Œæœ›ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of a study on the anti-cancer effects of sulforaphane from cruciferous vegetables. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like human cells or animals, arrows or flow lines to indicate the steps of the experiment, and a section highlighting the main results, such as protective effects or directional changes in cancer cell behavior.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°å…¶ç™‚æ•ˆçš„çœ‹æ³•ä»ç„¶å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶å°šæœªå®Œå…¨äº†è§£ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥çš„ç ”ç©¶å°æ–¼ç¢ºèªè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡æ²»ç™‚ä¸­çš„è§’è‰²åŠå…¶å®‰å…¨æ€§æ˜¯éå¸¸é‡è¦çš„ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€éåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€šè·¯ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­æœ‰10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥çš„å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–åˆ†æä¹Ÿé¡¯ç¤ºSTAT1æ°´å¹³èˆ‡è‡ªé–‰ç—‡é¢¨éšªä¹‹é–“å­˜åœ¨åå‘é—œè¯ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆæä¾›äº†æ”¯æŒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡ç—‡ç‹€æœ‰æ½›åŠ›ï¼Œä½†ç›®å‰å°å…¶ç™‚æ•ˆçš„çœ‹æ³•ä»ç„¶å­˜åœ¨çˆ­è­°ï¼Œä¸”å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶å°šæœªå®Œå…¨äº†è§£ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥çš„ç ”ç©¶å°æ–¼ç¢ºèªè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡æ²»ç™‚ä¸­çš„è§’è‰²åŠå…¶å®‰å…¨æ€§æ˜¯éå¸¸é‡è¦çš„ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€éåˆ†æç¾æœ‰çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€šè·¯ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­æœ‰10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ç”Ÿç‰©ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥çš„å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–åˆ†æä¹Ÿé¡¯ç¤ºSTAT1æ°´å¹³èˆ‡è‡ªé–‰ç—‡é¢¨éšªä¹‹é–“å­˜åœ¨åå‘é—œè¯ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆæä¾›äº†æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªè˜¿è””ä¹Ÿèƒ½å¹«åŠ©æ”¹å–„è‡ªé–‰ç—‡ï¼Ÿé€™å¯ä¸æ˜¯éš¨ä¾¿èªªèªªçš„ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨åœ¨ã€Œè˜¿è””ç¡«ç´ ã€é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œå®ƒä¸»è¦å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©è‡ªé–‰ç—‡æ‚£è€…æ”¹å–„ç¤¾äº¤åæ‡‰ï¼Œä»¥åŠå®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚\n\nç ”ç©¶åœ˜éšŠåˆ†æäº†å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æ¶‰åŠ333ååƒèˆ‡è€…ï¼Œä¸¦ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ã€‚\n\nğŸ” é‡è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ã€‚\n3. éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„ç§‘å­¸ç™¼ç¾å§ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane and autism. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like people or cells), arrows or flow lines indicating the steps of the experiment, and a section labeled 'Main Results' showing the protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢ï¼Œé€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç§»æ¤æ‰‹è¡“å¾Œï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œé€™å¯èƒ½å°æ”¹å–„ç§»æ¤çµæœæœ‰å¹«åŠ©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å¢å¼·ç§»æ¤æ‰‹è¡“çš„æˆåŠŸç‡ï¼Œä¸¦æ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤æ‰‹è¡“å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºç›®å‰ç§»æ¤æ‚£è€…åœ¨æ¥å—å…ç–«æŠ‘åˆ¶æ²»ç™‚å¾Œï¼Œä»ç„¶é¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸å¿…è¦çš„ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚ä»–å€‘é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦è©•ä¼°æ°´å‡è† å°æ–¼ç§»æ¤å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ æ°´å‡è† çš„æ²»ç™‚çµ„å°é¼ åœ¨ç§»æ¤å¾Œçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ï¼Œè€Œæœªæ¥å—æ²»ç™‚çš„å°é¼ åœ¨ç¬¬9å¤©æ™‚å‰‡å®Œå…¨å¤±å»ç§»æ¤å™¨å®˜ã€‚çµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶ä¸­å¯èƒ½æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„å€™é¸ç‰©è³ªã€‚",
    "explanation_zh": "åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢ï¼Œé€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚ç§»æ¤æ‰‹è¡“å¾Œï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œé€™å¯èƒ½å°æ”¹å–„ç§»æ¤çµæœæœ‰å¹«åŠ©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å¢å¼·ç§»æ¤æ‰‹è¡“çš„æˆåŠŸç‡ï¼Œä¸¦æ¸›å°‘æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤æ‰‹è¡“å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºç›®å‰ç§»æ¤æ‚£è€…åœ¨æ¥å—å…ç–«æŠ‘åˆ¶æ²»ç™‚å¾Œï¼Œä»ç„¶é¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸å¿…è¦çš„ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚ä»–å€‘é–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡ä¾›é«”å°é¼ çš„çš®è†šç§»æ¤åˆ°æ¥å—è€…å°é¼ èº«ä¸Šï¼Œä¸¦è©•ä¼°æ°´å‡è† å°æ–¼ç§»æ¤å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ æ°´å‡è† çš„æ²»ç™‚çµ„å°é¼ åœ¨ç§»æ¤å¾Œçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ï¼Œè€Œæœªæ¥å—æ²»ç™‚çš„å°é¼ åœ¨ç¬¬9å¤©æ™‚å‰‡å®Œå…¨å¤±å»ç§»æ¤å™¨å®˜ã€‚çµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤å™¨å®˜çš„å­˜æ´»æ™‚é–“ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœªä¾†çš„å™¨å®˜ç§»æ¤ç ”ç©¶ä¸­å¯èƒ½æ˜¯ä¸€å€‹æœ‰å‰æ™¯çš„å€™é¸ç‰©è³ªã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å¹«åŠ©æˆ‘å€‘çš„èº«é«”æ›´å¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœå’Œå…¶ä»–åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æˆåˆ†ï¼Œå¯èƒ½å°ç§»æ¤æ‰‹è¡“å¾Œçš„æ€¥æ€§æ’æ–¥åæ‡‰æœ‰ç©æ¥µå½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒï¼Œä¸¦å¸Œæœ›æ‰¾å‡ºå®ƒåœ¨ç§»æ¤å™¨å®˜å­˜æ´»æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œé–‹ç™¼äº†ä¸€ç¨®å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ä»–å€‘è§€å¯Ÿåˆ°ï¼Œé€™ç¨®æ°´å‡è† èƒ½é¡¯è‘—æé«˜å°é¼ çš„ç§»æ¤å™¨å®˜å­˜æ´»ç‡ï¼Œä¸¦æ¸›å°‘ç‚ç—‡ç´°èƒçš„æ•¸é‡ã€‚\n\né€™äº›çµæœè®“äººæ„Ÿåˆ°æŒ¯å¥®ï¼Œå› ç‚ºå®ƒé¡¯ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨æå‡ç§»æ¤æ‰‹è¡“æˆåŠŸç‡æ–¹é¢çš„æ½›åŠ›ï¼\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç§»æ¤å¾Œçš„æ€¥æ€§æ’æ–¥åæ‡‰ã€‚\n2. ä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ²»ç™‚çµ„å°é¼ å­˜æ´»ç‡é”åˆ°80%ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å™¨å®˜ç§»æ¤æä¾›äº†æ–°çš„æ€è·¯ï¼Œå€¼å¾—æˆ‘å€‘é—œæ³¨ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of the study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified representations of experimental subjects like mice or cells, and arrows or flow lines showing the experimental procedure. Include a section labeled 'Main Findings' highlighting protective effects and changes observed, using a soft color palette on a white or light background.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºã€‚éš¨è‘—äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œäº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­åšå‡ºæ›´å¥½çš„é¸æ“‡ï¼Œé€²è€Œé™ä½ç™Œç—‡é¢¨éšªã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ï¼Œå¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªBaxå’ŒBcl-2ã€‚é€™äº›ç ”ç©¶æ–¹æ³•ä¸»è¦æ˜¯é€šéåˆ†æå·²æœ‰çš„æ–‡ç»å’Œå¯¦é©—æ•¸æ“šï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ½›åœ¨çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”ä¹Ÿè€ƒæ…®äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å„ªå‹¢ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä½œç”¨ï¼Œä¸¦ä¸”å¯èƒ½é€šéå½±éŸ¿å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©ä¾†é”æˆé€™äº›æ•ˆæœã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å±•ç¾å‡ºå¸Œæœ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èˆ‡ç¾ä»£é†«å­¸çµåˆï¼Œç‚ºæ–°è—¥çš„é–‹ç™¼æä¾›äº†éˆæ„Ÿã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºã€‚éš¨è‘—äººå€‘å°å¥åº·é£²é£Ÿçš„é‡è¦–ï¼Œäº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­åšå‡ºæ›´å¥½çš„é¸æ“‡ï¼Œé€²è€Œé™ä½ç™Œç—‡é¢¨éšªã€‚\n\né€™ç¯‡ç¶œè¿°ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ï¼Œå¦‚è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç™Œç—‡çš„ç™¼å±•æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªBaxå’ŒBcl-2ã€‚é€™äº›ç ”ç©¶æ–¹æ³•ä¸»è¦æ˜¯é€šéåˆ†æå·²æœ‰çš„æ–‡ç»å’Œå¯¦é©—æ•¸æ“šï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ½›åœ¨çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”ä¹Ÿè€ƒæ…®äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å„ªå‹¢ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä½œç”¨ï¼Œä¸¦ä¸”å¯èƒ½é€šéå½±éŸ¿å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©ä¾†é”æˆé€™äº›æ•ˆæœã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å±•ç¾å‡ºå¸Œæœ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èˆ‡ç¾ä»£é†«å­¸çµåˆï¼Œç‚ºæ–°è—¥çš„é–‹ç™¼æä¾›äº†éˆæ„Ÿã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤æ¡Œä¸Šç«Ÿç„¶è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼ä»Šå¤©è¦è·Ÿå¤§å®¶èŠèŠä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡åŒ–åˆç‰©ï¼Œå®ƒä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘çš„è”¬èœã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸Šå¯èƒ½æœ‰è‘—ä¸å°çš„å¹«åŠ©ã€‚\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºï¼Œç ”ç©¶è€…å€‘æ¢è¨äº†å®ƒå¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œé€²è€Œå½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ï¼Œé‚„æœ‰å…¶ä»–åƒæ˜¯è¡€ç®¡ç”Ÿæˆå’Œç‚ç—‡åæ‡‰ç­‰éç¨‹ã€‚\n\nç ”ç©¶åœ˜éšŠå›é¡§äº†å¾ˆå¤šè³‡æ–™ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ å°ä¸€äº›ç”Ÿç‰©æ¨™è¨˜ç‰©ï¼ˆæ¯”å¦‚ç´°èƒå‡‹äº¡ç›¸é—œçš„è›‹ç™½è³ªï¼‰æœ‰é¡¯è‘—å½±éŸ¿ï¼Œé€™äº›éƒ½æ˜¯èˆ‡ç™Œç—‡æœ‰é—œçš„æŒ‡æ¨™ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­å±•ç¾äº†å¸Œæœ›ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å…·é«”æ•ˆæœã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼èª¿ç¯€ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ã€‚\n2. å®ƒçš„ä½œç”¨å¯èƒ½èˆ‡å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©æœ‰é—œã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥æ¢ç´¢ï¼",
    "image_prompt": "Create an infographic that explains the research on sulforaphane, a compound found in cruciferous vegetables like broccoli. Include simplified illustrations of broccoli and sulforaphane, along with simplified representations of experimental subjects such as cells or animals. Use arrows or flow lines to indicate the experimental process. Include a section labeled 'Key Findings' highlighting potential protective effects and changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„æ•ˆæœï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶ç›®å‰çš„ç ”ç©¶çµæœé¡¯ç¤ºæ”¹å–„ä¸¦ä¸é¡¯è‘—ï¼Œä½†é€™ä»ç„¶ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†åŸºç¤ï¼Œå¯èƒ½æœƒä¿ƒé€²æ›´æ·±å…¥çš„æ¢ç´¢ï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†è¼”åŠ©æ²»ç™‚ç²¾ç¥ç–¾ç—…çš„é ˜åŸŸã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œé€šå¸¸æœƒå½±éŸ¿å€‹é«”çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦è©•ä¼°å…¶å°èªçŸ¥åŠŸèƒ½å’Œä»£è¬æŒ‡æ¨™çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–æ¬¡é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œå°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†è³‡æ–™ï¼ŒåŒ…æ‹¬PubMedã€Scopusã€Web of Scienceå’ŒCochrane Centralï¼Œç¯„åœæ¶µè“‹è‡³2025å¹´4æœˆã€‚ä»–å€‘ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œå°ˆæ³¨æ–¼è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶åˆ†æäº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ï¼Œä¸»è¦è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬é™½æ€§å’Œé™°æ€§ç—‡ç‹€é‡è¡¨çš„è®ŠåŒ–ï¼Œä»¥åŠèªçŸ¥æ¸¬é‡å’Œä»£è¬æ¨™è¨˜çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„é™½æ€§ç—‡ç‹€å’Œç¸½é«”ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±æ™‚ï¼Œé™°æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„åˆæ­¥è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„æ•ˆæœï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶ç›®å‰çš„ç ”ç©¶çµæœé¡¯ç¤ºæ”¹å–„ä¸¦ä¸é¡¯è‘—ï¼Œä½†é€™ä»ç„¶ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†åŸºç¤ï¼Œå¯èƒ½æœƒä¿ƒé€²æ›´æ·±å…¥çš„æ¢ç´¢ï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨é£²é£Ÿä¸­çš„å¤©ç„¶æˆåˆ†ä¾†è¼”åŠ©æ²»ç™‚ç²¾ç¥ç–¾ç—…çš„é ˜åŸŸã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œé€šå¸¸æœƒå½±éŸ¿å€‹é«”çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œä¸¦è©•ä¼°å…¶å°èªçŸ¥åŠŸèƒ½å’Œä»£è¬æŒ‡æ¨™çš„å½±éŸ¿ã€‚é€™æ˜¯é¦–æ¬¡é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œå°æ–¼ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nç ”ç©¶åœ˜éšŠé€²è¡Œäº†ä¸€ç³»åˆ—çš„æ–‡ç»æœå°‹ï¼Œå¾å¤šå€‹è³‡æ–™åº«ä¸­æ”¶é›†è³‡æ–™ï¼ŒåŒ…æ‹¬PubMedã€Scopusã€Web of Scienceå’ŒCochrane Centralï¼Œç¯„åœæ¶µè“‹è‡³2025å¹´4æœˆã€‚ä»–å€‘ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œå°ˆæ³¨æ–¼è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶åˆ†æäº†å››é …RCTï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ï¼Œä¸»è¦è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬é™½æ€§å’Œé™°æ€§ç—‡ç‹€é‡è¡¨çš„è®ŠåŒ–ï¼Œä»¥åŠèªçŸ¥æ¸¬é‡å’Œä»£è¬æ¨™è¨˜çš„è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„é™½æ€§ç—‡ç‹€å’Œç¸½é«”ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±æ™‚ï¼Œé™°æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„æ‚£è€…ä¸­ï¼Œåœè—¥ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„åˆæ­¥è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥å¥åº·æœ‰ä¸€äº›å°å¹«åŠ©ï¼é€™æ˜¯ä¸€é …é‡å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç ”ç©¶ï¼Œè®“æˆ‘å€‘ä¾†çœ‹çœ‹é€™äº›æœ‰è¶£çš„ç™¼ç¾ï¼\n\nç ”ç©¶äººå“¡æƒ³çŸ¥é“è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœå’Œè˜¿è””ä¸­çš„å¤©ç„¶æˆåˆ†ï¼‰æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ã€‚ä»–å€‘é€²è¡Œäº†ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†369åæ‚£è€…çš„æ•¸æ“šï¼Œè©•ä¼°äº†ä»–å€‘çš„é™½æ€§å’Œé™°æ€§ç—‡ç‹€ï¼Œä»¥åŠä¸€äº›èªçŸ¥å’Œä»£è¬æŒ‡æ¨™ã€‚\n\nçµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å°é™½æ€§ç—‡ç‹€çš„æ”¹å–„æ•ˆæœä¸æ˜é¡¯ï¼Œä½†åœ¨é™°æ€§ç—‡ç‹€ä¸Šæœ‰è¼•å¾®çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œå®ƒé‚„èƒ½é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼Œåƒæ˜¯è†½å›ºé†‡å’Œä¸‰é…¸ç”˜æ²¹è„‚ï¼Œé€™å°æ–¼æ•´é«”å¥åº·ä¾†èªªæ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°ç²¾ç¥åˆ†è£‚ç—‡çš„æŸäº›ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºå…¶èƒ½é™ä½ä¸€äº›ä¸è‰¯çš„ä»£è¬æŒ‡æ¨™ã€‚  \n3. æœªä¾†çš„ç ”ç©¶å¯èƒ½æœƒé€²ä¸€æ­¥æ¢ç´¢é£²é£Ÿå°ç²¾ç¥å¥åº·çš„å½±éŸ¿ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of sulforaphane on schizophrenia. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines to indicate the experimental steps, and a section clearly labeled 'Main Results' that highlights the observed effects, such as improvements in negative symptoms and reductions in certain metabolic markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦å’Œèƒå…’çš„å¥åº·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚ç‰¹åˆ¥æ˜¯å°æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³çš„ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å­•å©¦å’Œèƒå…’å…å—å¦Šå¨ é«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚é€™æ¨£çš„ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ æœŸé–“å¦‚ä½•æ”¹å–„æ¯é«”å’Œèƒå…’çš„å¥åº·æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å­•å©¦ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”é€™ç¨®è½‰ç§»æ˜¯å¦æœƒå°èƒå…’çš„å¥åº·ç”¢ç”Ÿå½±éŸ¿ã€‚é€™æ˜¯ç¬¬ä¸€å€‹åœ¨äººé«”ä¸­ç ”ç©¶è˜¿è””ç¡«ç´ æ¯èƒè½‰ç§»çš„å¯¦é©—ï¼Œå…·æœ‰é‡è¦çš„è‡¨åºŠæ„ç¾©ã€‚",
    "para3": "å¯¦é©—å°è±¡ç‚ºå…«åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚åƒèˆ‡ç ”ç©¶ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ã€‚æ‰‹è¡“æ™‚ï¼Œé‚„æ”¶é›†äº†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆå­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨å­•å©¦å’Œèƒå…’ä¹‹é–“è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿æä¾›äº†æ–°çš„ç·šç´¢ï¼Œä¸¦é–‹å•Ÿäº†ç›¸é—œç ”ç©¶çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦å’Œèƒå…’çš„å¥åº·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚ç‰¹åˆ¥æ˜¯å°æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³çš„ç–¾ç—…ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›å°‘å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å­•å©¦å’Œèƒå…’å…å—å¦Šå¨ é«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚é€™æ¨£çš„ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨å¦Šå¨ æœŸé–“å¦‚ä½•æ”¹å–„æ¯é«”å’Œèƒå…’çš„å¥åº·æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å­•å©¦ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”é€™ç¨®è½‰ç§»æ˜¯å¦æœƒå°èƒå…’çš„å¥åº·ç”¢ç”Ÿå½±éŸ¿ã€‚é€™æ˜¯ç¬¬ä¸€å€‹åœ¨äººé«”ä¸­ç ”ç©¶è˜¿è””ç¡«ç´ æ¯èƒè½‰ç§»çš„å¯¦é©—ï¼Œå…·æœ‰é‡è¦çš„è‡¨åºŠæ„ç¾©ã€‚\n\nå¯¦é©—å°è±¡ç‚ºå…«åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚åƒèˆ‡ç ”ç©¶ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ã€‚æ‰‹è¡“æ™‚ï¼Œé‚„æ”¶é›†äº†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2åˆ°4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆå­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨å­•å©¦å’Œèƒå…’ä¹‹é–“è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿æä¾›äº†æ–°çš„ç·šç´¢ï¼Œä¸¦é–‹å•Ÿäº†ç›¸é—œç ”ç©¶çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå¯èƒ½å°å­•å©¦å’Œèƒå…’æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼é€™é …æ–°ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨å­•å©¦ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å°å¦Šå¨ é«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚\n\nç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™ç¨®æˆåˆ†æ˜¯å¦èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”é€™æ¨£çš„è½‰ç§»æœƒå°èƒå…’å¥åº·ç”¢ç”Ÿä»€éº¼å½±éŸ¿ã€‚ä»–å€‘æ‹›å‹Ÿäº†å…«åå¥åº·å­•å©¦ï¼Œåœ¨å‰–è…¹ç”¢å‰çµ¦å¥¹å€‘æœç”¨è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“éç¨‹ä¸­æ”¶é›†äº†å¥¹å€‘çš„è¡€æ¶²ã€å°¿æ¶²å’Œè‡å¸¶è¡€æ¨£æœ¬ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å­•å©¦çš„è¡€æ¶²ã€èƒç›¤å’Œæ¯ä¹³ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯é¦–æ¬¡è­‰å¯¦é€™ç¨®æˆåˆ†å¯ä»¥åœ¨æ¯èƒä¹‹é–“è½‰ç§»ã€‚é›–ç„¶æœ‰äº›å­•å©¦åœ¨æ‰‹è¡“ç•¶å¤©çš„è¡€å£“ç•¥æœ‰ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šä¸¦æœªå‡ºç¾æ˜é¡¯è®ŠåŒ–ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„å½±éŸ¿æä¾›äº†æ–°ç·šç´¢ï¼Œè®“æˆ‘å€‘å°å­•å©¦å’Œèƒå…’çš„å¥åº·ä¿è­·æœ‰äº†æ›´å¤šæœŸå¾…ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¦Šå¨ é«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚\n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ å¯ä»¥åœ¨å­•å©¦å’Œèƒå…’ä¹‹é–“è½‰ç§»ã€‚\n3. æœªä¾†å¯èƒ½é–‹å•Ÿæ›´å¤šé—œæ–¼å­•å©¦å¥åº·çš„æ–°ç ”ç©¶æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of sulforaphane (found in radishes) on pregnant women. Use a flat design style with a light background and soft colors. Include symbols for radishes or sulforaphane, simplified icons representing study subjects (like people or cells), arrows or flow lines to show the experiment steps, and a section labeled 'Main Results' that highlights protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè‡Ÿç—…çš„æ²»ç™‚å’Œé é˜²æä¾›äº†ä¸€äº›æ–°çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚ä¸­ï¼Œå¸¸å¸¸éœ€è¦ä½¿ç”¨å†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™ç¨®ç™‚æ³•å¯èƒ½æœƒå¼•ç™¼ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€ æˆéå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ã€‚é€™äº›æ´»æ€§æ°§æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆæå®³ï¼Œå› æ­¤æ‰¾åˆ°èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„è—¥ç‰©æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ¸›å°‘å¿ƒè‡Ÿç—…æ‚£è€…çš„æå‚·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›åŒ–åˆç‰©å¦‚ä½•é€šéæ¿€æ´»Nrf2é€šè·¯ä¾†æ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ´»æ€§æ°§ï¼Œä¸¦ä¸”å¸Œæœ›é€éçµæ§‹æ”¹è‰¯ä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯3gåŒ–åˆç‰©ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­ï¼Œä»¥è§€å¯Ÿå…¶å°ç¼ºæ°§å†æ°§åˆæå‚·çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…æ¸¬é‡äº†ç´°èƒä¸­çš„æ´»æ€§æ°§æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠç™¼ç‚å› å­çš„åˆ†æ³Œï¼Œä¸¦é€²è¡Œäº†ç©©å®šæ€§ç ”ç©¶ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œæ¸›å°‘å¹…åº¦é”24.5%ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½ç™¼ç‚å› å­TNF-Î±çš„åˆ†æ³Œä¸Šä¹Ÿæœ‰è‰¯å¥½çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢çš„æ•ˆæœä¹Ÿç›¸ç•¶é¡¯è‘—ï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåŒ–åˆç‰©å¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè‡Ÿç—…çš„æ²»ç™‚å’Œé é˜²æä¾›äº†ä¸€äº›æ–°çš„å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚ä¸­ï¼Œå¸¸å¸¸éœ€è¦ä½¿ç”¨å†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™ç¨®ç™‚æ³•å¯èƒ½æœƒå¼•ç™¼ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€ æˆéå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰ã€‚é€™äº›æ´»æ€§æ°§æœƒå°å¿ƒè‡Ÿç´°èƒé€ æˆæå®³ï¼Œå› æ­¤æ‰¾åˆ°èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„è—¥ç‰©æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› ç‚ºå…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ¸›å°‘å¿ƒè‡Ÿç—…æ‚£è€…çš„æå‚·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·é€²è¡Œæ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ä¾†æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›åŒ–åˆç‰©å¦‚ä½•é€šéæ¿€æ´»Nrf2é€šè·¯ä¾†æ¸›å°‘å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ´»æ€§æ°§ï¼Œä¸¦ä¸”å¸Œæœ›é€éçµæ§‹æ”¹è‰¯ä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯3gåŒ–åˆç‰©ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­ï¼Œä»¥è§€å¯Ÿå…¶å°ç¼ºæ°§å†æ°§åˆæå‚·çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…æ¸¬é‡äº†ç´°èƒä¸­çš„æ´»æ€§æ°§æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠç™¼ç‚å› å­çš„åˆ†æ³Œï¼Œä¸¦é€²è¡Œäº†ç©©å®šæ€§ç ”ç©¶ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œæ¸›å°‘å¹…åº¦é”24.5%ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½ç™¼ç‚å› å­TNF-Î±çš„åˆ†æ³Œä¸Šä¹Ÿæœ‰è‰¯å¥½çš„æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢çš„æ•ˆæœä¹Ÿç›¸ç•¶é¡¯è‘—ï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„æ²»ç™‚åƒ¹å€¼ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåŒ–åˆç‰©å¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿä¹Ÿéœ€è¦ä¿è­·ï¼Œå°±åƒæˆ‘å€‘çš„çš®è†šä¸€æ¨£ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°å¿ƒè‡Ÿç—…çš„æ²»ç™‚æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œï¼Œå¿ƒè‡Ÿå¯èƒ½æœƒå—åˆ°çš„æå‚·ï¼Œå°¤å…¶æ˜¯å†çŒæ³¨ç™‚æ³•å¸¶ä¾†çš„å•é¡Œã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©èƒ½å¤ å¹«åŠ©æ¸›å°‘å¿ƒè‡Ÿç´°èƒä¸­çš„æ´»æ€§æ°§ï¼Œé€™äº›æ´»æ€§æ°§æœƒé€ æˆç´°èƒæå‚·ã€‚ ç ”ç©¶ä¸­ï¼Œä»–å€‘åˆæˆäº†ä¸€ç¨®åç‚º3gçš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦åœ¨å¯¦é©—ä¸­æ¸¬è©¦å®ƒå°å¿ƒè‡Ÿå¾®è¡€ç®¡çš„ä¿è­·æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œ3gèƒ½æœ‰æ•ˆæ¸›å°‘æ´»æ€§æ°§çš„ç”¢ç”Ÿï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼é™ä½ç™¼ç‚å› å­ï¼Œç”šè‡³åœ¨æŠ—è…«ç˜¤æ–¹é¢ä¹Ÿè¡¨ç¾ä¸éŒ¯ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚çš„ä¸€å€‹æ–°å¸Œæœ›ã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿç´°èƒæå‚·ã€‚\n2. 3gåŒ–åˆç‰©é¡¯è‘—é™ä½æ´»æ€§æ°§å’Œç™¼ç‚å› å­ã€‚\n3. è˜¿è””ç¡«ç´ æˆ–è¨±åœ¨æŠ—è…«ç˜¤æ–¹é¢ä¹Ÿæœ‰æ½›åŠ›ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on a compound called sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section that highlights the main results, such as protective effects and changes in reactive oxygen levels.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Acute Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨æ–¹é¢ã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºå¯èƒ½æœƒå°ç´°èƒé€ æˆæå®³ï¼Œé€²è€Œå°è‡´å„ç¨®å¥åº·å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œå…¶ä»–åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨ä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«é€™äº›åŒ–åˆç‰©çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç¶­æŒèº«é«”çš„å¥åº·ï¼Œä¸¦æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®å«åšesculinçš„åŒ–åˆç‰©ï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­çš„å½±éŸ¿ã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› çš„å› å­ï¼Œé€™äº›åŸºå› æœ‰åŠ©æ–¼å°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿Nrf2çš„æ´»åŒ–åŠå…¶å¾ŒçºŒçš„æŠ—æ°§åŒ–ä½œç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinå’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ç‰©ã€æ°®æ°§åŒ–ç‰©ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é›¢å’Œå…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2åœ¨esculinå’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­çš„ç´°èƒæ ¸å®šä½ï¼Œé€™è­‰å¯¦äº†Nrf2çš„è½‰ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯å±•ç¾å‡ºèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„æŠ—æ°§åŒ–æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨æ–¹é¢ã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºå¯èƒ½æœƒå°ç´°èƒé€ æˆæå®³ï¼Œé€²è€Œå°è‡´å„ç¨®å¥åº·å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œå…¶ä»–åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨ä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«é€™äº›åŒ–åˆç‰©çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç¶­æŒèº«é«”çš„å¥åº·ï¼Œä¸¦æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®å«åšesculinçš„åŒ–åˆç‰©ï¼Œåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­çš„å½±éŸ¿ã€‚Nrf2æ˜¯ä¸€ç¨®èƒ½å¤ å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› çš„å› å­ï¼Œé€™äº›åŸºå› æœ‰åŠ©æ–¼å°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿Nrf2çš„æ´»åŒ–åŠå…¶å¾ŒçºŒçš„æŠ—æ°§åŒ–ä½œç”¨ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinå’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ç‰©ã€æ°®æ°§åŒ–ç‰©ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é›¢å’Œå…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•ä¾†è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2åœ¨esculinå’Œè˜¿è””ç¡«ç´ è™•ç†çµ„ä¸­çš„ç´°èƒæ ¸å®šä½ï¼Œé€™è­‰å¯¦äº†Nrf2çš„è½‰ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯å±•ç¾å‡ºèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„æŠ—æ°§åŒ–æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”å°±åƒä¸€åº§åŸå ¡ï¼ŒæŠ—æ°§åŒ–åŠ‘å°±åƒåŸå ¡çš„å®ˆè¡›ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæ“‹å¤–ä¾†çš„æ”»æ“Šï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinï¼ˆé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼æŸäº›æ¤ç‰©ä¸­çš„å¤©ç„¶æˆåˆ†ï¼‰ï¼Œå®ƒå€‘åœ¨ä¿è­·æˆ‘å€‘ç´°èƒæ–¹é¢çš„æ½›åŠ›ã€‚\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯çœ‹çœ‹é€™å…©ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ä¸€å€‹å«åšNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­èƒ½å•Ÿå‹•ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æˆ‘å€‘çš„èº«é«”å°æŠ—æ°§åŒ–æå‚·ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œè®“å®ƒå€‘åˆ†åˆ¥æ¥è§¸é€™å…©ç¨®åŒ–åˆç‰©ï¼Œä¸¦è§€å¯Ÿäº†å¤šç¨®æŒ‡æ¨™ã€‚\n\nçµæœç™¼ç¾ï¼Œesculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½é¡¯è‘—æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä¸¦ä¿ƒé€²æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼è€Œä¸”Nrf2åœ¨é€™å…©çµ„ä¸­çš„ç´°èƒæ ¸å®šä½ä¹Ÿå¾—åˆ°äº†è­‰å¯¦ï¼Œé¡¯ç¤ºå®ƒå€‘çš„æŠ—æ°§åŒ–æ•ˆæœç›¸ä¼¼ã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n- è˜¿è””ç¡«ç´ å’Œesculinéƒ½èƒ½å¹«åŠ©æˆ‘å€‘çš„ç´°èƒæŠµæŠ—æ°§åŒ–æå‚·ã€‚\n- é€™äº›åŒ–åˆç‰©èƒ½ä¿ƒé€²æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ã€‚\n- Nrf2åœ¨é€™äº›éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·å¤šåƒäº›å¯Œå«é€™äº›å¤©ç„¶æˆåˆ†çš„é£Ÿç‰©ï¼Œå®ˆè­·æˆ‘å€‘çš„å¥åº·å§ï¼",
    "image_prompt": "Create an infographic illustrating the experiment and main findings of a study on antioxidant compounds, specifically sulforaphane and esculin. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like zebrafish, arrows or flow lines indicating the experimental steps, and a section clearly labeled 'Main Findings' showing protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  }
]